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ABSTRACT 
It was reported that mitochondrial aconitase was particularly susceptible to oxidative 
damage among those mitochondrial proteins because the electrophilicity of the fourth labile 
iron atom in its labile Fe-S cluster renders it especially sensitive to oxidative inactivation by 
nucleophilic superoxide anion. In addition, an aconitase inhibition-cascade was proposed to 
increase lipogenesis, slow lipolysis, increase feed intake, and decrease energy expenditure, 
which together resulted in obesity development. Therefore, combining the susceptibility of 
mitochondrial aconitase to oxidative damage with the above aconitase inhibition cascade, it 
was hypothesized in this study that oxidative stress contributed to obesity development by 
initiating the aconitase inhibition-cascade. We tested this hypothesis experimentally in two 
different fashions by using medium fat (MF) diet and mitochondrially targeted vitamin E 
(MitoVit E). Specifically, we hypothesized that MF diet contributes to obesity development 
by initiating the aconitase inhibition cascade, whereas MitoVit E can improve obesity 
development by reversing the aconitase inhibition cascade.  
Sixty-four 7-week-old C57BL/6J male mice, after fed a high fat diet (60 kcal% from 
fat) for 5 weeks, were assigned randomly to 4 groups. Group I and III were fed a low fat diet 
(10 kcal% from fat) and a MF diet (32 kcal% from fat), respectively, with each group 
gavaged with drug vehicle (0.9% NaCl solution); Group II and IV were fed the same diets as 
Group I and II, respectively, with each group gavaged with 40 mg MitoVit E/kg body weight. 
Gavage was conducted every other day for 5 weeks. We showed that 1) oxidative stress is 
elevated with obesity development; 2) MitoVit E decreased MF diet-induced body weight 
gain (P < 0.05) without affecting feed intake; 3) MitoVit E decreased lipid deposition in liver 
(P < 0.001) and adipose tissues (P < 0.001) while increasing muscle mass (P < 0.05); 4) 
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MitoVit E systemically decreased MF diet-induced oxidative stress indicated by a decrease 
of urinary isoprostane/creatinine; 5) MitoVit E acted in a tissue specific manner by 
decreasing mitochondrial H2O2 production rate (P < 0.01), which attenuated the inhibition of 
aconitase activity (P < 0.05), increased protein oxidation (P < 0.01), and consequently 
increased ATP production rate (P < 0.05), only in liver, but not in muscle; 6) MitoVit E 
significantly increased the number and size of subsarcolemmal mitochondria in the soleus (P 
< 0.05); 7) MitoVit E upregulated gene expression of acyl-CoA oxidase in liver (P < 0.05) 
and adipose tissue (P < 0.01) and carnitine palmitoyltransferase 1 in liver (P < 0.001), 
indicating MitoVit E enhanced peroxisomal and mitochondrial fatty acid oxidation. 8) 
MitoVit E, however, did not affect either those genes (such as fatty acid synthase and acetyl-
CoA carboxylase) involved in lipogenesis in liver and adipose tissue or lipoprotein lipase 
involved in deposition of serum triacylglycerol in adipose tissue or hormone-sensitive lipase 
involved in lipolysis in adipose tissue.   
Therefore, we concluded that 1) MitoVit E might play a role in energy partitioning by 
favoring elevated energy expenditure in adipose tissue and preserving energy storage in 
skeletal muscle; 2) MitoVit E decreases fat deposition in liver and white adipose tissue not 
by reversing “aconitase inhibition cascade” as we proposed, instead, through enhancing 
peroxisomal (in liver and adipose tissue) and mitochondrial (in liver) fatty acid oxidation. 
Taken together, all the evidence shown in our study indicates that MitoVit E merits 
additional research as an anti-obesity agent. 
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INTRODUCTION: THESIS ORGANIZATION 
This thesis is presented as one complete paper with abstract, introduction, materials 
and methods, result, discussion, conclusion, acknowledgement and feferences for submission 
to the Journal of Nutrition. The title of the paper is “Mitochondrially targeted vitamin E 
normalizes mitochondrial oxidative stress, increases mitochondrial density, and inhibits fat 
deposition in mice”. The thesis was prepared from research conducted to partly fulfill the 
requirements for a Master of Science degree. The data indicate that 1) mitochondrially 
targeted vitamin E effectively decreases systematic oxidative stress, and also mitochondrial 
oxidative stress in liver but not in muscle; 2) mitochondrially targeted vitamin E decreases 
diet-induced lipid deposition in liver and adipose tissues in C57BL/6 mice through enhancing 
fatty acid oxidation without affecting either de novo lipogenesis or deposition of plasma 
triacylglycerols. The paper is preceded by a literature review and followed by a general 
discussion and future research. 
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LITERATURE REVIEW  
Mitochondrial formation of reactive oxygen species 
Mitochondria are often referred to as the “powerhouse” of the cells because they 
consume nearly 90% of cells’ oxygen to support oxidative phosphorylation for the synthesis 
of ATP, the energy currency used for a variety of metabolic reactions. Degradation of dietary 
nutrients via glycolysis, fatty acid oxidation, and amino acid oxidation results in a transfer of 
substrate electrons to two high-energy electron donors, NADH and FADH2, which then 
deliver electrons to the electron transport chain (ETC) located in the inner mitochondrial 
membrane at Complex I and II, respectively (shown in Fig. 1). These electrons are 
subsequently transported along the respiratory chain Complexes (I-IV) in ETC, to the final 
electron acceptor oxygen. The energy released by the flow of electrons through ETC is used 
to pump protons from the matrix to the intermembrane space of mitochondria, which creates 
an electrochemical gradient across the mitochondrial inner membrane. This transmembrane 
proton gradient is used to drive the ATP synthesis as protons re-enter the mitochondrial 
matrix through the F0F1 ATP synthase (Complex V) (1).  
Ideally, during this process, we assume all electrons are transferred along the ETC 
until they finally reduce oxygen to form water. However, in reality, single electrons leak at 
some redox centers in the ETC and partially reduce oxygen to superoxide anion (O2.-), the 
precursor of most reactive oxygen species (ROS) and a mediator in oxidative chain reactions 
(2). Either spontaneously or through a reaction catalyzed by superoxide dismutase (SOD), 
O2.- can be converted to a more stable product, hydrogen peroxide (H2O2), which can diffuse 
freely through membranes into the cytosol or the nucleus, resulting in oxidative damage to 
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many cell compartments. Furthurmore, hydrogen peroxide can react with reduced transition 
metals (in particular iron and copper), known as Fenton reaction, to produce hydroxyl radical 
(OH·), one of the strongest oxidants in nature. In turn, those oxidized transition metals after 
Fenton reaction can be re-reduced by  O2.- to propagate this process (3). In addition, O2.- can 
also react with nitric oxide (NO·) to produce another very powerful oxidant, peroxynitrite 
(ONOO-) (4). Although not the focus of this review, the oxidants derived from NO· are called 
reactive nitrogen species (RNS). 
 
Figure 1. Mitochondrial electron transport chain. (Adapted from Trifunovic and Larsson, 2007) 
 
Although a variety of mitochondrial sources of O2.- including several respiratory 
Complexes (Complex I (5,6), Complex II (7,8), and Complex III (9,10)) and individual 
enzymes (11-13) have been reported, two key respiratory sites that have been suggested to 
play an important role in O2.- production are cytochrome bc1 Complex and the NADH 
dehydrogenase Complex (14). However, the relative contribution of every site to the overall 
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O2.- production varies from organ to organ. Turrens et al. reported that Complex III is 
responsible for most of the O2.- generation in heart and lung mitochondria (15,16) whereas 
Barja et al. found that Complex I appears to be the primary source of O2.- production in the 
brain under normal conditions (17,18).  Based on the equation (d [O2.-]/d t = k [O2] [R·]) 
given by Turrens et al., the rate of  O2.- production by the respiratory chain increases when 
the concentration of oxygen and electron donors (R·) increases(16). Many of ageing studies 
suggested a high correlation between that oxygen consumption and O2.- generation, which, in 
turn, explained that lower oxygen consumption could lead to longer longevity for queen bees 
and houseflies without wings because of lower O2.- generation (19). In addition, hyperoxia 
was reported to increase ROS generation and resultant products of oxidative damage (20).  
On the other hand, technique of increasing electron donors (R·) by slowing down the electron 
flow in the ETC is also commonly used in the laboratory. Two classic examples are removal 
of ADP and addition of Complex inhibitors. In the absence of ADP (State IV respiration), 
movement of H+ through ATP synthase ceases and consequently the H+ gradient builds up, 
which causes electron flow to slow down and the respiratory chain to become more reduced, 
leading to an increase in O2.- production (2). For the addition of Complex inhibitors (e.g., 
rotenone, which inhibits Complex I, or antimycin, an inhibitor of Complex III), these 
Complex inhibitors can trap those electrons in those carriers upstream the site of inhibition 
and make them fully reduced, contributing to an increased formation of O2.-. Furthurmore, 
different combinations of substrates and inhibitors specific for distinct segments of the 
respiratory chain are used to determine the sites of oxygen radical generation in functional 
mitochondria. The details of these methods were nicely described by Barja (21). Specifically, 
an increase in oxygen radical production following the addition of an inhibitor means that the 
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oxygen radical generation site is located in the carrier upstream of the site of inhibition, 
whereas a decrease in oxygen radical production following the addition of an inhibitor 
indicates that the generator must be situated downstream the site of inhibition (21). For 
example, the higher oxygen radical production observed in the presence than in the absence 
of rotenone in pyruvate/malate-supplemented rat mitochondria indicates that they produce 
ROS at Complex I because this is the only Complex situated on the substrate side of the 
inhibitor in this experiment (22). Similarly, the classically described increase in H2O2 
production after addition of antimycin A to succinate-supplemented rat heart mitochondria is 
the result of their capacity to produce ROS at Complex III (23,24). Another classic example 
is that addition of rotenone to mitochondria respiring with succinate decreases ROS 
production, indicating that part of the ROS generated with this substrate comes from 
Complex I because rotenone can block the reverse electron flow from succinate to Complex I 
and thus its capacity for ROS production (21). 
Oxidative damage to mitochondrial DNA, proteins, and lipids 
ROS are well recognized for playing a dual role as both deleterious and beneficial 
species. When moderate amounts of ROS are produced, they specifically regulate 
intracellular signaling pathways by reversible oxidation of proteins such as transcription 
factors or protein kinases (25). However, when these ROS are chronically produced at high 
rates, they can have deleterious effects by massive and irreversible oxidation of their 
principals targets, i.e., DNA, lipids, and proteins (19). Early studies on isolated mitochondria 
suggested that 1-4% of the total oxygen consumed was used to generate ROS (26). However, 
subsequent studies, under more physiological conditions, have estimated this basal value to 
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~0.2% of the consumed oxygen (27). This even much lower estimated value of ROS 
generation still does not change the following fact that the ETC still remains the major site 
(~90%) of ROS production in the cell, leading to the suggestion that mitochondria also are 
the prime targets for oxidative damage (28). In the following, oxidative damages to 
mitochondrial DNA, lipids, and proteins are briefly discussed.  
Oxidative damage to mitochondrial DNA  
Compared with nuclear DNA, oxidative damage to mitocondrial DNA (mtDNA) is 
more extensive and persists longer (29), mainly because 1) the location of the mtDNA is in 
close proximity to the inner mitochondrial membrane where considerable quantities of free 
radicals (e.g., O2.- and H2O2) are produced; 2) large iron stores located in the mitochondria 
react with free radicals (e.g., H2O2), leading to reactive free radical intermediates (e.g., OH·) 
that seriously damage mtDNA; 3) mitochondrial DNA repair capacity is limited because 
mitochondria lack entirely the feature of nucleotide excision repair; 4) mtDNA does not 
contain histones, which may act as a physical barrier against ROS in the nuclear genome; 5) 
mtDNA has a high transcription rate, thus providing a high probability of mutations and/or 
deletions; 6) oxidative damage to mtDNA could lead to lethal injury because all the 
polypeptides, transfer RNAs (tRNAs), and ribosomal RNAs (rRNAs) that mtDNA encodes 
are essential for electron transport and ATP generation and consequently for normal cellular 
physiology (30); 7) mtDNA damage following oxidative stress increased production of H2O2 
(31), indicating the initiation of a vicious cycle of ROS propagation and mtDNA oxidation.  
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Oxidative damage to mitochondrial lipid   
ROS generated within the mitochondria attack not only mtDNA, but also those 
phospholipids in the mitochondrial inner membrane. It is well known that the hydroxyl 
radical generated via Fenton chemistry can initiate lipid peroxidation, which consists of three 
stages: initiation, propagation, and termination. Although general lipid peroxidation has been 
extensively studied, study on oxidative damage to specific mitochondrial lipids is lacking. 
However, a classic example of a specific mitochondrial lipid sensitive to oxidative damage is 
cardiolipin, which is a phospholipid bound to cytochrome c on the inner mitochondrial 
membrane (a nice reveiw was given in reference (30)). Under normal physiological 
conditions, cardiolipin anchors cytochrome c protein to mitochondrial membrane where it 
participates in electron transport between Complexes III and IV of the respiratory chain (30). 
A previous study has demonstrated that peroxidation of cardiolipin abolishes cytochrome c 
binding (32), which is consistent with the finding that ROS decreased the content of 
cardiolipin in inner mitochondrial membrane, whereas addition of exogenous cardiolipin but 
not peroxidized cardiolipin restored the content of cardiolipin (33). Besides, the unsaturated 
nature of the acyl chains of cardiolipin renders this biomolecule susceptible to peroxidation 
by ROS (30). It has been proposed that oxidation of cardiolipin can make cyrochrome c 
available for release into the cytosol upon permeabilization of the outer mitochondrial 
membrane, subsequently resulting in the activation of the caspase cascade that brings about 
most of the biochemical and morphological alterations characteristic of apoptosis (30).   
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Oxidative damage to mitochondrial protein  
Mitochondrial proteins containing labile iron-sulfur (Fe-S) are extremely vulnerable 
to oxidative damage because the electrophilicity of the unligated, acid-labile iron atoms in 
the labile Fe-S clusters renders them especially sensitive to oxidative inactivation by 
nucleophilic O2.- (34). Mitochondrial aconitase is one of these labile Fe-S proteins and 
involved in an important mechanism of O2.- toxicity: oxidation and inactivation of labile Fe-S 
cluster in mitochondrial aconitase by O2.- can result in the release of Fe2+ and H2O2, both of 
which are ingredients of the Fenton reaction and can result in generation of the potent 
OH· amplifying O2.--initiated oxidative damage. Mitochondrial aconitase is such an 
intriguing protein that its oxidation and resultant inactivation by ROS has been proposed to 
be one of the mechanisms contributing to ageing (20), obesity development (35), and 
Parkinson disease (PD) (30). On the other hand, recently, a model of the redox regulation by 
a superoxide-aconitase rheostat has been proposed that inhibition of mitochondrial aconitase 
provides a feedback mechanism regulating ROS production by slowing the Krebs cycle and 
decreasing electron flux through the ETC and resultant ETC-derived O2.- (14).  Therefore, a 
critical question arises is whether mitochondrial aconitase is a “circuit breaker” for redox 
regulation or the culprit for those oxidative stress-induced diseases mentioned above. This 
question will be discussed in details in an independent section later in this review. 
Biomarkers of oxidative damage to DNA, lipids, and proteins  
The only technique that can directly measure free radicals is electron spin resonance 
(ESR) where a trap molecule is used to react with the radicals to measure the energy changes 
that occur as unpaired electrons align in response to an external magnetic field (36). 
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Although spin-trap ESR techniques can have enough specificity compared with other 
techniques such as chemiluminescence and fluorometry, the sensitivity of these ESR 
techniques is limited and they require expensive equipment. Therefore, the most extensively 
used approach for studying ROS is to measure the products of lipid, protein, and DNA 
oxidation caused by ROS. 
Biomarkers of oxidative DNA damage 
 Currently, five oxidative bases produced by ROS attack on DNA are being studied 
and used for biomarkers of oxidative DNA damage: 8-hydroxyguanine, thymine glycol, 5-
hydroxymethyluracil, formylamidopyrimidine, and 8-hydroxydeoxyadenine (37). Among 
those five biomarkers, 8-hydroxyguanine (8-OH-G) is the product most frequently measured 
as an indicator of oxidative DNA damage. Whether a particular type of DNA modification 
such as 8-OH-G can represent the overall DNA mutagenesis by ROS is being questioned. 
However, it is likely, although so far the strong evidence has been lacking, that the formation 
of 8-OH-G is proportional to that of other DNA modifications; therefore, measurement of 8-
OH-G should be very useful in estimating ROS-induced damage (38). In addition, guanine is 
known to be one of the most reactive targets during the formation of the adducts with adenine, 
guanine, cytosine, and thymine when hydroxyl radical attacks the components of the DNA 
molecule (39). The presence of 8-OH-G in human urine was first reported by Ames and co-
workers in 1989 (40). Subsequently, in 1991, Nishimura and co-workers observed formation 
of 8-OH-G from deoxyguanosine in high yield by a Fenton-type hydroxyl radical-generating 
system (41). This oxidized DNA is both relatively easily formed and is mutagenic and 
carcinogenic. Therefore, 8-OH-G is not only a good biomarker of oxidative stress of an 
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organism, but also a potential biomarker of carcinogenesis (19). Many analytical techniques 
have been developed to measure oxidative DNA base damage. High-performance liquid 
chromatography-electrochemical detection and gas chromatography-mass spectrometry 
(GC/MS) are the two traditional and classic methods. Currently, the arsenal of methods 
available include the promising high-performance liquid chromatography-tandem mass 
spectrometry technique, capillary electrophoresis, 32P-postlabeling, antibody-base 
immunoassays, and assays involving the use of DNA repair glycosylases such as the comet 
assay (42).  
Biomarkers of oxidative lipid damage  
Thiobarbituric reactive acid substances (TBARS) and F2-isoprostanes (8-epiPGF2α) 
are two most commonly used indicators of lipid peroxidation damage.  
TBARS  It is known that polyunsaturated fatty acids can be attacked by ROS (e.g. 
hydroxyl radical) to produce peroxy radicals (ROO·), which subsequently can be rearranged 
via a cyclization reaction to endoperoxides (precursors of malondialdehyde) with the final 
product of the peroxidation process being malondialdehyde (MDA) (43,44). Thiobarbituric 
acid (TBA) test is based on the reaction of TBA with MDA. The sample to be tested is 
heated with TBA under acidic conditions, and the absorbance of pink MDA-TBA adduct 
produced is measured at 532 nm or by fluorescence at 553 nm (45). Instead of being specific 
for MDA, TBA test measures all the TBA-reactive substances (TBARS) including aldhydes 
other than MDA and also those substances not related to lipid peroxidation such as sugars, 
amino acids, and biliruin (46). Application of a GC/MS assay for MDA has indicated that the 
commonly used TBARS assay overestimates the actual MDA concentrations by more than 
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10-fold (46). However, TBA assays could be more reliable by combining it with HPLC 
where TBA reaction mixture is separated first and then the specific peak of the MDA-TBA 
adduct is quantified, therefore minimizing interference with other compounds and increasing 
the specificity (36).   
F2-isoprostanes The F2-isoprostanes are a family of prostaglandin-like compounds 
produced by non-enzymatic peroxidation of arachidonic acids. In the Biomarkers of 
Oxidative Stress Study (BOSS), a recent multi-investigator study sponsored by the National 
Institutes of Health (NIH), it was found that the most accurate method to assess in vivo 
oxidant stress status is the quantification of plasma or urinary F2-isoprostanes (47). The 
following favorable characteristics of F2-isoprostanes make it a gold-standard biomarker of 
oxidative stress status in vivo (48): 1) stable compounds; 2) specific products of lipid 
peroxidation; 3) present in detectable quantities in all normal biological tissues and fluids, 
thus allowing the definition of a normal range; 4) amounts increase substantially in animal 
models of oxidant injury; 5) amounts are modulated by antioxidant status; 6) amounts are 
unaffected by lipid content in the diet. In total, 64 F2-isoprostanes isomers (four subfamilies 
with 16 diastereoisomers in each family) can be formed during peroxidation of arachidonic 
acid (49,50). Of these, 8-epi-PGF2α (also known as 8-iso- PGF2α) has received most attention 
because it has been shown to possess certain adverse biological activities (51,52). The 
quantification of urinary 8-epi-PGF2α is generally considered as superior to the measurement 
of circulating plasma 8-epi-PGF2α because of the following reasons (53,54): 1) 8-epi-PGF2α is 
cleared rapidly from the circulation (within approx. 16 min), which implies that its 
quantification in the circulation will only provide information regarding a discrete point in 
time (55); 2) More chances of artefactual generation of 8-epi-PGF2α in plasma can occur with 
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improper sample handling and/or prolonged storage than in urine (53). If serum or plasma 
samples are used, flash-freezing is usually suggested. For urine samples, standardization of 
urinary isoprostane concentration by creatinine should be considered. Gas or liquid 
chromatography coupled with mass spectrometry (GC/MS or LC/MS) is the gold standard 
method with its high sensitivity and specificity, which yields quantitative results in the low 
picogram range (56). However, the disadvantage of this technique is that it is time-
consuming and also requires expensive equipments. Alternative methods have been 
developed to quantify F2-isoprostanes using immunological approaches. Antibodies against 
8-epi-PGF2α have been generated and at least three immunoassay kits are available 
commercially (56). The drawback of  these immunoassays is that they sacrifice specificity 
because of possible cross-reactions with other prostanoids (36).  It has been suggested that 
comparison of amounts of F2-isoprostanes derived from mass spectrometry method and from 
enzyme immunoassay is not appropriate because they are not numerically equivalent (57).  
However, as long as these immunoassays can have a good correlation with mass 
spectrometry methods, their low cost and relative ease of use still attract researchers to use 
for comparing the treatment effect between groups.  
Other markers related to lipid peroxidation include malondialdehyde (MDA), 
conjugated dienes, breath hydrocarbons, and 4-hydroxynenal (4HNE). In addition, some 
other indirect biomarkers such as the lag time for oxidation of lipid molecules and their 
capacity to scavenge or trap oxgen radicals are also used to indicate the susceptibility or 
resistance of lipids to free radical attack (58).  
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Biomarkers of oxidative protein damage  
There are numerous different types of oxidative protein damage because there are so 
many mechanisms for induction of protein oxidation and because all of the amino acyl side 
chains can become oxidatively modified (59). These have been summarized and nicely 
discussed elsewhere (60). However, currently the most sensitive assay for oxidative protein is 
the measurement of carbonyl group formation, which results from the reaction of reactive 
free radical such as the hydroxyl radical with amino acyl moieties such as lysine, arginine, 
proline, and threonine. Protein carbonyl as a marker of oxidative stress has the advantage of 
being more stable and therefore lasting longer in the plasma or urine over products of lipid 
peroxidation and oxidative DNA damage; for example, protein carbonyl in the serum is 
stable for at least 4 hours, whereas 8-epi-PGF2α is cleared rapidly from the circulation within 
approx. 16 min. However, compared with other types of protein modification, measurement 
of carbonyls has the disadvantage of being nonspecific because carbonyls can be induced by 
almost all types of ROS and, hence, do not shed significant light on the source of the 
oxidative stress (60). Some other specific protein modifications such as the conversion of 
tyrosine residues to 3-chlorotyrosine, 3-nitrotyrosine or dityrosine, were proposed to be the 
better markers of oxidative stress. However, these markers can still not be as commonly used 
as protein cabornyl because their concentrations in tissue are orders of magnitude lower than 
the carbonyl content, which requires highly sensitive and expensive methods (60,61). 
Various sensitive methods have been developed to detect protein carbonyl contents. Many of 
the methods involve derivitization of the carbonyl group with dinitrophenylhydrazine 
(DNPH), which leads to formation of a stable dinitrophenyl hydrazone product, which then 
can be detected mainly by the following several methods. 1) The DNP group absorbs 
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ultraviolet (UV) light at 370 nm, which allows its determination by quantification of its 
absorbance. This spectrophotometric method has the advantage of simplicity, but it requires 
more protein than may be available and also washing steps can give rise to variability (62). 2) 
Spectrophotometric method coupled with HPLC can reduce the variability and also increase 
sensitivity and specificity. 3) Anti-DNP antibodies can be used to quantify carbonyl content 
via enzyme-linked immunosorbent assay (ELISA) or western blot. This method requires only 
micrograms of protein and also correlates well with the spectrophotometric method (62). 
Shown in Fig. 2 are two general schemes for measuring protein carbonyls by using either 
spectrophotometric assay or immunoassay. 
 
Figure 2. Two common methods for using DNPH to test for protein carbonyls: immunoassay and 
spectrophotometric assay. (adapted from Emily Shacter, 2000 ) 
Antioxidant defense system 
In order to balance the effect of ROS, aerobic organisms develop antioxidant defense 
systems, which include both non-enzymatic and enzymatic antioxidants. Enzymatic 
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antioxidants include superoxide dismutase (SOD), glutathione peroxidase (GPx), and 
catalase (CAT) (63). Non-enzymatic antioxidants are represented by ascorbic acid (vitamin 
C), α-tocopherol (vitamin E), thiol antioxidants (glutathione and lipoic acid), and other 
antioxidants (64). All these antioxidants are involved in the following pathways shown in Fig. 
3.  
Enzymatic antioxidants  
1) SOD is the antioxidant that catalyzes the dismutation of O2.- to O2 and the less-
reactive species H2O2. In humans, there are three forms of SOD: cytosolic Cu/Zn-SOD, 
mitochondrial Mn-SOD, and extracellular SOD (65,66). SOD destroys O2.- by successive 
oxidation and reduction of the transition metal ion at the active site in a Ping Pong type 
mechanism with remarkably high reaction rates (67). 2) CAT is located in the peroxisome 
where it functions to catalyze the decomposition of H2O2 to water and oxygen (68). CAT has 
one of the highest turnover numbers of all enzymes: one molecule of catalase can convert ~6 
million molecules of H2O2 to water and oxygen each minute (19). 3) GPx acts in conjunction 
with the tripeptide glutathione (GSH) to decompose either H2O2 or an organic peroxide 
ROOH to water or alcohol while simultaneously oxidizing GSH. GPx is the major source of 
protection against low levels of oxidative stress and competes with catalase to eliminate 
H2O2 as potential substrate for the Fenton reaction.  
Non-enzymatic antioxidants  
1) Vitamin C is a very important and powerful antioxidant that works in aqueous 
environment. At physiological pH, 99.9% of vitamin C is present as AscH-.  AscH- reacts 
with α-tocopherol radicals to regenerate α-tocopherol and poorly reactive radical Asc.- (see 
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Fig. 2). The concentration of Asc.- is a good measure of the degree of oxidative stress in 
biological systems (69,70). 2) Vitamin E is a fat-soluble vitamin that exists in eight different 
forms. α-Tocopherol is the most active form of vitamin E in humans and is a powerful 
biological antioxidant that is considered to be the major membrane-bound antioxidant 
employed by the cell (71). The main antioxidant function of vitamin E is the protection 
against lipid peroxidation. As shown in Fig. 3, the lipid peroxyl radical (LOO·) reduced by α-
tocopherol results in the formation of a lipid hydroperoxide and α-tocopherol radical  and 
escapes from lipid peroxidation. As mentioned above, the α-tocopherol radical then can be 
reduced back to the original α-tocopherol by vitmin C. 3) GSH, or the tripeptide γ-
glutamylcysteinylglycine, is highly abundant in the cytosol (1-11 mM), nuclei (3-15 mM), 
and mitochondria (5-11 mM) and is the major soluble antioxidant in these cell compartments 
(72). The reduced form of glutathione is GSH, and the oxidized form is GSSG, glutathione 
disulfide (see Fig. 4). The ratio of GSH/GSSG is a good measure of oxidative stress of an 
organism (73). The main protective roles of GSH against oxidative stress are (72): that (i) 
GSH is a cofactor of several detoxifying enzymes against oxidative stress, e.g. GPx, 
glutathionetransferase and others; (ii) GSH scavenges H2O2 and lipid peroxides by the 
catalytic action of glutathionperoxidase; (iii) GSH is able to regenerate the most important 
antioxidants, vitamin C (directly) and vitamin E (indirectly) back to their active forms. 4) α- 
Lipoic acid is both water and fat-soluble and therefore is widely distributed in both cellular 
membranes and the cytosol. α-Lipoic acid (ALA) is readily absorbed from the diet and is 
converted rapidly in many tissues to its reduced dithiol form, dihydrolipoic acid (DHLA) (see 
Fig. 5) (74). The DHLA/ALA couple has a redox potential of -320 mV, and so DHLA has 
one of the highest antioxidant potentials known in biological systems (75). Shown in Fig. 3 
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(reaction 10), DHLA can reduce GSSG and Asc.- back to their reduced forms, GSH and 
AscH-, respectively, with itself being converted to ALA, indicating that DHLA is capable of 
regenerating other antioxidants from their radical or inactive forms. 5) Other non-enzymatic 
antioxidants include carotenoid, flavonoids, coenzyme Q10, and antioxidant minerals 
(selenium, zinc, copper, and manganese ions). All these primary antioxidants work 
cooperatively to maintain the pro-oxidant-antioxidant balance and prevent oxidative damage. 
 
Figure 3. The various pathways in the antioxidant defense system. (adapted and modified from 
Valko et al., 2005). Reaction (1): superoxide is dismutated by the superoxide dismutase (SOD) to 
hydrogen peroxide. Reaction (2): hydrogen peroxide is most efficiently scavenged by the enzyme 
glutathione peroxidase (GPx) which requires GSH as the electron donor. Reaction (3): the oxidized 
glutathione (GSSG) is reduced back to GSH by the enzyme glutathione reductase (Gred), which uses 
NADPH as the electron donor. Reaction (4): in the presence of some transition metals (e.g., Fe2+, Cu+ 
and others), hydrogen peroxide can be converted to the reactive hydroxyl radical (Fenton reaction). 
Reaction (5): the hydroxyl radical can abstract an electron from polyunsaturated fatty acid (LH) to 
give rise to a carbon-centered lipid radical (L·). Reaction (6): the lipid radical can further interact 
with molecular oxygen to give a lipid peroxyl radical (LOO·). Reaction (7): the lipid peroxyl radical 
(LOO·) is reduced within the membrane by the reduced form of vitamin E (T-OH), resulting in the 
formation of a lipid hydroperoxide and a radical of vitamin E (T-O·). Reaction (8): the regeneration 
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of vitamin E by vitamin C: the vitamin E radical (T-O·) is reduced back to vitamin E (T-OH) by 
ascorbic acid (the physiological form of ascorbate is ascorbate monoanion, AscH-) leaving behind 
the ascorbyl radical (Asc·-). Reaction (9): the regeneration of vitamin E by GSH: the oxidized 
vitamin E radical (T-O·) is reduced by GSH. Reaction (10): the oxidized glutathione (GSSG) and the 
ascorbyl radical (Asc·-) are reduced back to GSH and ascorbate monoanion, AscH-, respectively, by 
the dihydrolipoic acid (DHLA), which is itself converted to α-lipoic acid (ALA). Reaction (11): the 
regeneration of DHLA from ALA using NADPH. Reaction (12): lipid hydroperoxides can break 
down into aldehydes, such as the strong oxidant 4-hydroxynonenal. Reaction (13): 4-
hydroxynonenal is rendered into an innocuous glutathiyl adduct (GST: glutathione S-transferase). 
Reaction (14): lipid hydroperoxides are reduced to alcohols and dioxygen by GPx using GSH as the 
electron donor. Reaction (15): hydrogen peroxide can also be converted to water and molecular 
oxygen by the enzyme catalase (CAT) located in the peroxisome.  
 
Figure 4. Structures of reduced (GSH) and oxidized (GSSG) glutathione. (adapted from Valko et al., 
2005) 
 
 
Figure 5. Stuctures of α-lipoic acid and dihydrolipoic acid. (adapted from Valko et al., 2005) 
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Aconitase: “circuit breaker” of redox metabolism or “culprit” in 
oxidative stress-induced diseases? 
Iron-sulfur cluster 
Aconitases are ancient and widely distributed enzymes that catalyse the sterospecific 
isomerization of citrate to isocitrate via cis-aconitate both in the Krebs and glyoxylate cycles 
(76). Aconitase contains an iron-sulfur cluster [4Fe-4S], acting both in the binding of the 
substrate at the active site and in the catalytic addition or removal of H2O. In this cluster (Fig. 
6), only three of the iron atoms are ligated directly to cysteines of the protein backbone, 
whereas the fourth iron is only ligated to inorganic sulfur of the cluster (77).  The 
electrophilicity of the fourth labile iron in the Fe-S cluster renders aconitase especially 
sensitive to oxidative inactivation by nucleophilic O2.-, which promotes the release of the 
fourth labile Fe from the [4Fe-4S]2+ cluster and the subsequent formation of a [3Fe-4S]2+ 
cluster with concomitant loss of enzyme activity (Figure. 5) (34). It is noted that not all Fe-S 
enzymes contain this labile Fe, such as xanthine oxidase and several of the mitochondrial 
ETC Complexes, which are not known to possess labile Fe-S center that would render them 
susceptible to oxidative inactivation (30).  
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Figure 6. Conversion between [4Fe-4S]2+ and [3Fe-4S]2+. (adapted from Beinert and Kennedy, 2005) 
Cytosolic aconitase, a two-faced protein: enzyme and iron regulatory factor 
In eukaryotes, two aconitase isoenzymes exist, one localized within the mitochondrial 
matrix and the other in the cytosols. The gene for Cytosolic aconitase is a gene distinct from 
that encoding the mitochondrial enzyme. For example, in humans, the mitochondrial enzyme 
is encoded by a gene located on chromosome 22, whereas the cytosolic enzyme is encoded 
by a gene on chromosome 9 (78). The discovery of significant amino acid sequence identity 
between mitochondrial aconitase and the iron-responsive element binding protein (IRE-BP) 
led to the realization that IRE-BP is an alternative form of cytosolic (not of mitochondrial) 
aconitase that is devoid of its cubane Fe-S cluster (77,79). Therefore, cytosolic aconitase, as a 
two-faced protein, is also an iron regulatory factor involving in regulation of iron metabolism 
(77). Specifically, the IRE-BP isolated from iron replete cells does not bind to RNAs 
containing the iron responsive element (IRE) such as in transferrin receptor (TfR) and iron 
storage protein ferritin and is fully active aconitase, whereas the IRE-BP isolated from iron-
deprived cells binds with high affinity to its target IRE and lacks aconitase activity (80). 
Binding of IRE-BP to the IREs leads to stabilization of the TfR mRNA and translational 
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inhibition of ferritin mRNAs, resulting in increased TfR-dependent iron uptake and 
decreased iron sequestration into ferritin, whereas decreased IRE-BP/IRE interactions  result 
in TfR mRNA degradation and ferritin translation, conversely leading to decreased iron 
uptake and increased iron storage in ferritin (81).   
Mitochondrial aconitase evolved as a “circuit breaker” 
Current views on the origin of mitochondria look to a α-proteobacterium 
endosymbiont as the ancestor (82). Interestingly, it was noted that during the evolution of the 
mitochondrion from its α-proteobacterium ancestor, mitochondria gave up their ancestors’ 
original aconitase A, which was similar to cytosolic aconitase in eukaryotes, and evolved the 
present day mitochondrial enzyme (82). Considering the fact that cytosolic and mitochondrial 
aconitases are equally effective as enzymes, why do mitochondria need to evolve a different 
aconitase? One of the reasons could be the difference in their sensitivity to oxygen-mediated 
inactivation. Although both aconitases are inactivated by exposure to oxygen, cytosolic 
aconitase seems to be less sensitive to air inactivation compared with mitochondrial aconitase 
(14,83,84). It seems to be paradoxical that aerobic organisms, which should have adopted the 
more stable cytosolic aconitase to protect from oxidative damage by exposure to oxygen, 
instead evolved the mitochondrial aconitase, which is more sensitive to oxidative damage 
(14,83). A similar situation is also witnessed in E. coli with coexistence of two forms of 
enzymes, an oxygen-insensitive aconitase A (AcnA) and an oxygen-sensitive aconitase B 
(AcnB) (14,76,83). It was found that AcnB is the major aconitase for logarithmic growth in 
aerobic E. coli, whereas repression of AcnB and induction of AcnA are seen in stationary 
phase or under oxidative stress (76,85), indicating that similar to mitochondrial aconitase in 
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eukaryotes, the more oxygen-sensitive aconitase is the primary aconitase in E. coli during 
aerobic metabolism (83). In 2002, Walden proposed that the evolutional significance of 
utilizing the more oxygen-sensitive aconitase either in the eukaryotic mitochondria or E. coli 
is that higher sensitivity to oxygen-mediated inactivation can provide a feedback mechanism 
regulating its activity and ROS production during respiration by slowing the Krebs cycle and 
decreasing electron flux through the ETC and resultant ETC-derived O2.- (83). This idea is 
very consistent with the “aconitase as a circuit breaker” theory proposed by Gardner and 
Fridovich back in 199l that under condition of incipient oxidative stress inactivation of 
aconitase by sensitivity to O2/ O2.- shuts off much of the flow of electrons from substrates, 
largely halting the ROS production and thereby sparing DNA and the cell membranes from a 
potentially lethal oxidative attack (86).  
Gardner and Fridovich continued to explain that O2/ O2.- sensitive aconitase is a 
“circuit breaker” rather than a “fuse” in that it can be reactivated by Fe (II) plus thiols, 
present in the cell, and thus need not be entirely replaced (86). This again corresponds to the 
“superoxide-aconitase rheostat” model proposed by Armstrong et al. in 2004 that 
mitochondrial aconitase has to be reversibly inactivated to operate as a rheostat (14). Shown 
in Figure 7 is an O2.--driven aconitase inactivation-reactivation cycle: aconitase containing 
[4Fe-4S]2+ clusters are attacked and oxidized by O2.- to form inactive aconitase containing 
oxidized [3Fe-4S]1+ accompanied by the release of one labile iron and formation of H2O2; 
repair of the oxidatively damaged [3Fe-4S]1+ center can rapidly occur through univalent 
reduction and ferrous ion insertion (87). Studies have shown that mitochondrial aconitase 
undergoes dynamic inactivation-reactivation in response to oxidative stress in both bacteria 
(88,89) and also mammalian cells (90). This rapid inactivation-reactivation may be another 
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evolutional advantage of mitochondrial aconitase over the cytosolic aconitase since the repair 
of cytosolic aconitase after oxidant-induced damage is much slower (91).  
 
Figure 7. The O2.--driven aconitase Fe-S center cycle. (Adopted from Gardner, 1997) 
Aconitase: Culprit in some oxidative stress-induced diseases 
In the “circuit breaker” model, mitochondria evolved a more oxygen-sensitive 
aconitase to protect themselves from excessive oxidative attack by inactivating this enzyme 
when exposed to excessive O2/ O2.-. It might be true that the inactivation of this enzyme 
could decrease the absolute number of ROS by shutting off the electron flux through ETC 
and resultant ETC-derived O2.-. However, whether the oxidative damage has been alleviated 
or not is being questioned considering a very important mechanism of O2.- toxicity that the 
release of Fe2+ and H2O2 (two ingredients of the Fenton reaction) after oxidation of 
mitochondrial aconitase, can result in generation of the potent OH·, which can oxidize 
mitochondrial proteins, DNA, and lipids, thereby amplifying O2.--initiated oxidative damage. 
Vasques-Vivar et al. did provide evidence by using ESR spin trapping experiments that O2.--
mediated inactivation of mitochondrial aconitase is a source of OH· formation by Fenton 
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chemistry initiated by the co-released Fe2+ and H2O2 (92).  In addition, in order for either 
“circuit breaker” or “superoxide-aconitase rheostat” mechanism to efficiently regulate the 
Krebs cycle and redox homeostasis, an absolute requirement should be the rapid and 
reversible inactivation of mitochondrial aconitase (14). Under normal redox conditions, the 
release of aconitase iron by O2.- and the resultant inactivation of its activity can be reversed. 
However, under some pathophysiological conditions in oxidative stress-induced diseases, 
such as ageing, obesity, and Parkinson’s Disease (PD), elevation in the rate of superoxide 
generation and resultant enhancement in the production of H2O2 and hydroxyl free radical 
may cause carbonylation and an irreversible inactivation of aconitase through metal-
dependent, site-specific oxidations, according to the mechanism proposed by Stadtman (93). 
In contrast with the “circuit breaker” model, Yan et al. proposed a completely 
opposite mechanism that inactivation of aconitase, instead of alleviating oxidative stress, 
would initiate a cascade with the potential to cause a dramatic increase in the cellular burden 
of oxidative damage (20).  They believed that inactivation of aconitase may block normal 
electron flow to oxygen, leading to an accumulation of reduced metabolites such as NADH 
(20). This condition has been termed “reductive stress” and can cause an increased 
production of ROS through autoxidation of the reduced metabolites, thus initiating a vicious 
cascade and further amplifying the oxidative damage to macromolecules (93,94). In addition, 
this mechanism of oxidative damage amplification by aconitase inactivation also consistently 
supports the finding of the exponential increase in oxidized proteins during ageing in flies, 
rodents, and humans (20). So now, a question arises for the discrepancy of these two 
mechanisms: does inactivation of aconitase by O2.- initiate a feedback mechanism to alleviate 
the oxidative stress attack or a feedforward loop to deteriorate the present oxidative damage?  
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However, these two seemingly paradoxical mechanisms could be explained by the hypothesis 
that there might be two different aconitase inactivation cascades under both normal and 
pathophysiological/ageing conditions. This hypothesis is further supported by recent findings 
that inhibition of aconitase has been proposed to be one of the mechanisms contributing to 
ageing (20), obesity development (35), and PD (30), confirming that the aconitase inhibition 
cascade under pathophysiological/ageing conditions is different from that evolutionally 
advantageous cascade found under normal conditions. The specific mechanisms of aconitase 
inhibition proposed for ageing, obesity development, and PD are briefly discussed as follows: 
Ageing has been proposed to be a consequence of the accumulation of random 
oxidative damage to cellular molecules, caused by ROS or RNS, produced under normal 
physiological conditions (95,96). However, Yan et al. proposed that oxidation of a specific 
protein, mitochondrial aconitase, is critical in controlling the rate of the aging process (20). 
This hypothesis was strongly supported by their findings: 1) utilizing an immunochemical 
probe for oxidatively modified proteins, they found mitochondrial aconitase is most sensitive 
to oxidative damage during ageing compared with other mitochondrial proteins; 2) oxidation 
of mitochondrial aconitase increased with ageing whereas a corresponding loss of enyzme 
activity decreased with ageing; 3) Oxidation of mitochondrial aconitase in the older flies was 
significantly increased compared with the younger flies with 70% higher enzyme activity; 4) 
experimental inactivation of aconitase by hyperoxia or fluoroacetate (aonitase inhibitor) 
shortened life span of the flies, indicating a causal relationship between aconitase  activity 
and life span. Accordingly, Zahavi and Tahori back in 1950s (97) had found that serum 
citrate of rabbits increased with age, which is consistent with this age-dependent inactivation 
of aconitase because inactivation of aconitase would accumulate citrate in the serum.   
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Aconitase inhibition has never been considered a cause of obesity until Wlodek and 
Gonzales (35) in 2003 proposed that inhibition of mitochondrial aconitase in tissues capable 
of fat synthesis may be a major factor leading to obesity development (see Fig. 8). According 
to their theory, if citrate can not be converted into isocitrate when aconitase is inhibited, it 
will accumulate in the mitochondria and then in the cytosol, which will result in high activity 
of acetyl-CoA carboxylase (ACC), the rate-limiting enzyme for lipogenesis, ultimately 
increasing fatty acid synthesis (35). Furthermore, higher activity of ACC and more resultant 
malonyl-CoA formation will feed back negatively on the concentration of carnitine 
palmitoyltransferase I (CPT I) and decrease the supply of fatty acids from the cytosol to the 
mitochondria for beta-oxidation (98). In addition, inactivation of aconitase disrupts the TCA 
cycle resulting in less ATP production, which is also a well-known mechanism of 
diminishing ATP production in the immune system as a defense mechanism for killing tumor 
cells and microorganisms by destroying their energy supply (99). Inadequate energy supply 
in the body will be transformed into increased appetite. Many studies have indicated that 
hepatic ATP concentrations, which act as a major sensor of energy status in the body, is 
inversely related to food intake (100-102). Finally, ATP deficiency caused by aconitase 
inactivation is connected with the feeling of fatigue, resulting in decreased energy 
expenditure (103,104). Therefore, taken together, this one event, inhibition of mitochondrial 
aconitase, is able to increase lipogenesis, slow lipolysis, increase feed intake, and decrease 
energy expenditure, which together will cause more fat deposition and obesity development. 
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Figure 8. Aconitase inhibition-cascade leads to obesity development. (adapted and modified from 
Wlodek and Gonzales, 2005). Mitochondrial aconitase is oxidized and inhibited by ROS, which 
results in increased mitochondrial citrate levels and decreased ATP production. Citrate is 
transported to cytosol and activates ACC (acetyl-CoA carboxylase) and fatty acid synthesis. ACC 
and malonyl-CoA inhibit CPT I (carnitine parmitoyltransferase I) and beta-oxidation. Decreased 
ATP production leads to increased food intake and decreased energy expenditure. 
PD is a chronic, and often devastating, progressive neurodegenerative disease 
associated with loss of dopaminergic neurons in the substantia nigra (105). Oxidative stress 
has been implicated to play a major role in the neuronal cell death associated with PD. The 
hypothesis that oxidative inactivation of mitochondrial aconitase contributes to neuronal 
injury in the mammalian brain was proposed (30). Firstly, this hypothesis is based on the O2·- 
toxicity by its direct oxidation and consequent inactivation of aconitases. O2·- toxicity 
includes not only its oxidative damage to Fe-S cluster in the aconitase but also the resultant 
product of reactive hydroxyl radical, which can oxidize mitochondrial proteins, DNA, and 
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lipids. Oxidative damage to these mitochondrial macromolecules has been evidenced to 
contribute to elevated oxidative stress (e.g. when Complex I is oxidized), mitochondrial 
dysfunction (e.g. when mtDNA and Complex I are oxidized) and apoptosis (e.g. when 
cardiolipin is oxidized) (28,30,36,50,106,107), all of which have been linked to death of 
dopaminergic neurons and related PD (108,109). Secondly, inhibition of mitochondrial 
aconitase could result in TCA dysfunction impacting energy production and, therefore 
neuronal viability (30). Thirdly, inhibition of mitochondrial aconitase could cause a change 
in the iron homeostasis, which could contribute to PD. Several studies by using various 
methods have demonstrated that total iron concentrations in the substantia nigra of PD 
patients are higher than age-matched controls (110-118). The release of free iron ions during 
the aconitase inactivation could bind and activate IREs in the mRNA of certain proteins (e.g., 
ferritin) and thereby modulate their translation (119), which possibly could cause an iron 
overload, leading to PD. Finally, PD is an age-related neurodegenerative disease. Therefore, 
any mechanisms of aconitase inactivation that contribute to ageing are also risk factors for 
PD development. 
Targeting antioxidants to mitochondria by conjugation to lipophilic 
cations: A promising therapy in the treatment of oxidative stress-
induced diseases 
Mitochondria are central to cell life and death. Mitochondria are not only heavily 
involved in energy metabolism as a “powerhouse” to every cell, but also they play important 
roles in programmed cell death (apoptosis) (30), redox metabolism (2,11), and iron and 
calcium homeostasis (30,120). Therefore, oxidative damage to mitochondria contributes to a 
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wide range of metabolic disorders including Parkinso’s disease (105,109), Huntington’s 
disease (121), Alzheimer’s disease (122,123), diabetes (124), obesity (35), fatty liver (125), 
and ageing (93,96). Accordingly, for the last three decades, antioxidant therapy has been 
intensively studied to prevent or treat these oxidative stress-induced diseases. Although 
previously antioxidants such as vitamin E, ubiquinol and N-acetyl cysteine have been 
reported to decrease mitochondrial ROS concentrations and consequently alleviate 
mitochondrial oxidative damage, their effectiveness is largely limited by their poor capacity 
to accumulate within mitochondria (126-128). Their limited delivery to mitochondria is 
better illustrated in clinical studies where vitamin E showed no benefits in Parkinson’s 
disease at all (129,130).  Meanwhile, the search for better and more effective antioxidants, 
which can increase the antioxidant capacity of the mitochondrial compartment, has never 
been stopped. The recent recognition of mitochondria as the major source and also vulnerable 
target of ROS has raised awareness of the need to develop antioxidants specifically targeted 
to mitochondria. The strategy of targeting antioxidants to mitochondria not only effectively 
and specifically accumulates antioxidants within mitochondria, but also allows the relative 
importance of mitochondrial and cytoplasmic oxidative stress for oxidative stress-induced 
diseases to be dissected out. 
During the last 10 years, great progress in developing mitochondrially targeted 
antioxidants has been made, which is exemplified by the exciting results from two series of 
mitochondrially targeted antioxidants, amino acid- and peptide-based antioxidants and 
triphenylphosphonium-based (TPP-based) antioxidants. Amino acid and peptide-based 
antioxidants utilized the transporter-dependent delivery of prodrugs and unique 
mitochondrial localization of enzymes that catalyzed the release of drugs from prodrugs, 
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whereas TPP-based antioxidants rely on the mitochondrial biophysical property of high 
negative internal potential (131). Although amino acid and peptide-based antioxidants have 
several advantages over TPP-based antioxidants including the ability to accumulate at the 
inner mitochondrial membrane and the ability to protect against mitochondrial depolarization 
(132),  they are not as extensively studied as TPP-based antioxidants and most of their results 
come from in vitro studies (132,133), and therefore will not be the focus of this review.  
The high negative potential across both the plasma membrane (-30 to -60 mV) and 
the mitochondrial inner membrane (-150 to -170 mV) generated by the proton gradient 
during the transfer of electron to O2 can enable the lipophilic TPP cation conjugated with 
bioactive molecules (such as antioxidants) to permeate lipid bilayers easily and to accumulate 
within mitochondria matrix (134). According to the Nernst equation, the uptake of lipophilic 
cations into mitochondria increases 10-fold for every 61.5-mV of membrane potential, 
leading to 5- to 10-fold accumulation by the plasma membrane (△ψp) and then another 100- 
to 500-fold accumulation by the mitochondrial membrane potential  (△ψm) (see Fig. 9) (134). 
Based on the above knowledge, Murphy and coworkers developed a series of cationic 
antioxidants (Fig. 10) that preferentially accumulated in mitochondria including TPP-
conjugated derivatives of ubiquinone (MitoQ) (135-138), tocopherol (MitoVit E) (139), 
lipoic acid (MitoLip) (140), spin traps (MitoTEMPOL) (141), and the peroxidase mimetic 
ebselen (MitoSOD) (142). However, among these TTP-conjugated antioxidants, MitoQ and 
MitoVit E are most intensively studied and will be the focus of this review.  
Both tocopherol and coenzyme Q are effective chain-breaking antioxidants that can 
prevent lipid peroxidation. Furthermore, both their resultant oxidized forms can be recycled 
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to their active reduced forms. These two properties make MitoQ and MitoVit E the best 
candidates for studying oxidative stress-induced diseases involving lipid peroxidation. 
 
Figure 9. Uptake of triphenylphosphonium cations by mitochondria within cells. (Adopted from 
Smith et al., 2003). The lipophilic triphenylphosphonium cation is covalently attached to a 
biologically active molecule (X) such as an antioxidant or pharmacophore. The lipophilic cation is 
accumulated 5- to 10-fold into the cytosol from the extracellular space by the plasma membrane (△
ψp) and then further accumulated 100- to 500-fold into the mitochondrial matrix by the 
mitochondrial membrane potential (△ψm). As these lipophilic cations pass directly through the lipid 
bilayer, they do not utilize specific uptake systems and have the potential to distribute to 
mitochondria in all organs, including the brain. 
MitoQ and MitoVit E have been used in a large range of mitochondrial and cell 
models where they show protection against oxidative damage. It is beyond the scope of this 
review to discuss all those experiments (138,139,143-148); however, highlighted here are 
those studies that showed advantages of targeted antioxidants over untargeted antioxidants. 
Both MitoQ and MitoVit E, after administered to mice by intravenous injection, can be 
rapidly cleared from the plasma and accumulate in those tissues most affected by 
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mitochondrial dysfunction, such as heart, brain, skeletal muscle, and liver (134). Furthermore, 
it is suggested that MitoQ and MitoVit E can effectively accumulate within mitochondria as 
indicated by visualization of IBTP (4-iodobutyltriphenylphosphonium iodide)-labeled 
proteins immunoblotting (134). In contrast, most untargeted antioxidants distribute around 
the body, with only a small fraction being taken up by the mitochondria (149). In addition, 
pretreatment of bovine aortic endothelial cells (BAEC) with MitoQ (1 µM) and MitoVit E (1 
µM) but not untargeted antioxidants (e.g., vitamin E) significantly abrogated H2O2- and lipid 
peroxide-induced 2’, 7’-dichloro-fluorescein fluorescence and protein oxidation (146). 
Furthermore, MitoQ and MitoVit E inhibited H2O2- and lipid peroxide-induced inactivation 
of Complex I and aconitase, transferrin receptor (TfR) overexpression, and mitochondrial 
uptake of 55Fe, on all of which untargeted ubiquinone and vitamine E elicited little or no 
effect (146). Consistently, another cell culture study showed that MitoQ protected 
mammalian cells from H2O2-induced apoptosis but not from apoptosis induced by 
staurosporine or tumor necrosis factor-α, whereas untargeted ubiquinone analogs were 
ineffective in preventing apoptosis (138). To summarize, the accumulation of MitoQ and 
MitoVit E by mitochondria protected them from oxidative damage far more effectively than 
did untargeted ubiquinone and vitamin E, suggesting that the accumulation of bioactive 
molecules within mitochondria does increase their efficacy. 
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Figure 10. Compound structures of TPP-conjugated antioxidants. (Adopted from Smith et al., 2003). 
The structures of some of the mitochondria-targeted antioxidants developed to date are shown, 
together with their proposed antioxidant activities. Targeted moieties include the superoxide 
dismutase mimetic M4043 (MitoSOD), ebselen (MitoPrx), TEMPOL (MitoTEMPOL), ubiquinone 
(MitoQ), vitamin E (MitoE), and lipoic acid (MitoLip). 
However, a big disadvantage of TPP-conjugated antioxidants is their toxicity issue 
because the extensive accumulation of lipophilic cations within isolated mitochondria can 
disrupt membrane integrity, respiration, and ATP synthesis (150). These negative effects of 
lipophilic cations on mitochondrial function will always limit the amounts of TPP-derived 
targeted antioxidants that can be used, and therefore it is essential that the compounds are 
effective antioxidants at concentrations well below those that disrupt function (149).  
Toxicity of MitoQ and MitoVit E has been tested in the female Swiss-Webster mice by 
Murphy and coworkers (134) . Single intravenous (i.v.) injections of MitoVit E up to 300 
nmol (~ 4-6 mg/kg) were well tolerated, and toxicity was evident at 500 nmol (~ 6-10 mg/kg) 
and above within 12 h of injection. MitoQ was better tolerated, with no toxicity at 750 nmol 
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(20 mg/kg) but toxicity was evident a 1000 nmol (27 mg/kg) (134). Administering 500 µM 
MitoVit E and MitoQ to mice in their drinking water could both last for at least 14 days 
without any toxic effect observed (134). In addition, we found in our pilot study (unpublished 
data) that MitoVit E at 6 mg/kg body weight per day administered via intraperitoneal 
injection (i.p.) for one week is toxic to the C57BL/6 mice as evidenced by a decrease in feed 
intake and body weight. This slight inconsistency might be attributed to their different 
species (Swiss-Webster vs. C57BL/6J), different ages (8-10 wk vs. 5 wk), different genders 
(female vs. male) and different administration routes (i.v. vs. i.p.). Although the amounts of 
TPP-derived targeted antioxidants could be limited by their toxicity issue, intramitochondrial 
concentration of MitoVit E and MitoQ fed at the safe dosage still can achieve roughly 
millimolar level, which is in the therapeutically effective range for many biologically active 
molecules. Moreover, MitoQ is now being developed as a pharmaceutical by Antipodean 
Pharmaceuticls Inc. (http://www.antipodeanpharma.com/) and is in Phase 2 trials for 
Parkinson’s disease and hepatitis C. Therefore, experience to date indicates that 
mitochondria-targeted antioxidants by conjugation with lipophilic TPP cations have a 
promising future for treating those oxidative stress-induced diseases.  
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Abstract 
Mitochondrial aconitase is very sensitive to oxidative stress and its resultant 
inhibition by oxidation was proposed to cause a cascade leading to obesity development. 
Therefore, we hypothesized that mitochondrially targeted vitamin E (MitoVit E) can improve 
obesity by normalizing the above aconitase-inhibition cascade. Sixty-four 7-week-old 
C57BL/6J male mice, after fed a high fat diet (60 kcal% from fat) for 5 weeks, were assigned 
randomly to 4 groups. Group I and III were fed a low fat diet (10 kcal% from fat) and a 
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medium fat diet (32 kcal% from fat), respectively, with each group gavaged with drug 
vehicle (0.9% NaCl solution); Group II and IV were fed the same diets as Group I and II, 
respectively, with each group gavaged with 40 mg MitoVit E/kg body weight. Gavage was 
conducted every other day for 5 weeks. We showed that 1) MitoVit E decreased lipid 
deposition in liver (P < 0.05) and adipose tissues (P < 0.05); 2) MitoVit E decreased 
mitochondrial H2O2 production rate (P < 0.01) and increased aconitase activity (P < 0.05) in 
liver but not in muscle; 3) MitoVit E increased subsarcolemmal mitochondrial density in the 
soleus (P < 0.05); 4) MitoVit E upregulated gene expression of acyl-CoA oxidase in liver (P 
< 0.05) and adipose tissue (P < 0.01) and carnitine palmitoyltransferase 1 in liver (P < 0.001). 
In conclusion, MitoVit E normalizes mitochondrial oxidative stress in a tissue-specific 
manner, increases subsarcolemmal mitochondrial density, and decreases lipid deposition in 
mice through enhancing fatty acid oxidation.   
Introduction 
Mitochondria are the major cellular sources of ROS and also the prime targets for 
oxidative damage. In 1997, Yan et al. reported that in houseflies, mitochondrial aconitase is 
particularly susceptible to oxidative damage among those mitochondrial proteins (1) because 
the electrophilicity of the fourth labile iron atom in its labile Fe-S cluster renders it especially 
sensitive to oxidative inactivation by nucleophilic O2.-. Furthermore, oxidative inactivation 
of aconitase can initiate a cascade with the potential to cause a dramatic increase in the 
cellular burden of oxidative damage (2). Six years later, Wlodek and Gonzales (3) proposed 
an “aconitase inhibition cascade” that inhibition of mitochondrial aconitase in tissues capable 
of fatty acid synthesis can lead to obesity development. According to their theory, citrate will
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accumulate within mitochondria when aconitase is inhibited, resulting in more citrate 
transported into the cytosol, which will activate acetyl-CoA carboxylase (ACC) and 
subsequent fatty acid synthesis (3). Additionally, higher activities of ACC and more resultant 
malonyl-CoA formation will feed back negatively on the activity of carnitine 
palmitoyltransferase I (CPT I) and decrease the supply of fatty acids from the cytosol to the 
mitochondria for beta-oxidation (4). Furthermore, inactivation of aconitase disrupts the 
tricarboxylic acid (TCA) cycle, resulting in less ATP production and subsequent inadequate 
energy supply in the body, which will be transformed into increased appetite. Several studies 
have indicated that hepatic ATP concentrations, which act as a major sensor of energy status 
in the body, are inversely related to food intake (5-7). Finally, ATP deficiency caused by 
aconitase inactivation is connected with the feeling of fatigue, resulting in decreased energy 
expenditure (8, 9). Taken together, this one event, inhibition of mitochondrial aconitase, is 
able to increase lipogenesis, slow lipolysis, increase feed intake, and decrease energy 
expenditure, which together will cause more lipid deposition and obesity development. 
Combining the susceptibility of mitochondrial aconitase to oxidative damage (1) with the 
above “aconitase inhibition cascade” (3), our central hypothesis is that oxidative stress 
contributes to obesity development by initiating “aconitase inhibition cascade”. (Fig. 1)  
Oxidative stress, however, has never been regarded as the cause of obesity, even 
though a growing body of evidence showed the elevated oxidative stress in obesity 
development (10-16). The cause of obesity, which is occurring at epidemic rates in the 
United States, has been largely attributed to modern westernized diets typically with medium 
fat and high sucrose. High intake and supply of glucose and lipid in cells (17-19), mice (19, 
20), and rats (20) have been shown to be associated with elevated production of ROS and 
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oxidized lipids, proteins, and nucleic acids. Although antioxidants such as vitamin E, 
ubiquinol, and N-acetyl cysteine have been reported to decrease mitochondrial ROS 
concentrations and consequently alleviate mitochondrial oxidative damage, their poor 
capacity to accumulate within mitochondria largely limits their effectiveness (21-23). 
Murphy and coworkers developed a series of mitochondrially targeted antioxidants by 
conjugation with triphenylphosphonium (TPP) cations, which can permeate lipid bilayers 
easily and accumulate 100- to 1000-fold within mitochondria (24, 25). One of the most 
extensively studied mitochondrially targeted antioxidants is TPP-conjugated tocopherol 
(MitoVit E), which has been shown to be far more effective than untargeted vitamin E in 
protecting mitochondria from oxidative damage (26, 27). In addition, Smith et al. (24) 
reported that mitochondrially targeted vitamin E (MitoVit E) can be administered orally, 
leading to their accumulation at potentially therapeutic concentrations in those tissues (heart, 
brain, liver, and muscle) most affected by mitochondrial dysfunction. Altogether, we 
hypothesized that 1) medium fat diet contributes to obesity development by initiating the 
aconitase inhibition cascade, and 2) MitoVit E can improve obesity development by 
reversing the aconitase inhibition cascade.  
Materials and Methods 
Chemicals 
Mitochondrially targeted vitamin E (MitoVit E) was synthesized by covalently 
attaching a triphenylphosphonium (TPP) cation to vitamin E. The synthetic route of MitoVit 
E (provided by Dr. George Kraus at Iowa State University, unpublished) consists of 
connecting two commercially availbe starting materials with boron trifluoride to generate a 
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bicyclic system. This is followed with an acetylation of the phenol, an oxidative cleavage of 
the alkene followed by the reduction to give an alcohol. Subsequent conversion to a chloride 
with phosphorous trichloride followed by phosphonium salt formation creates the desired 
compound. Subequently, vitamin E component was covalently attached to the TPP cation. 
MitoVit E in our study has 3 carbons in the alkyl chain connecting the TPP and vitamin E 
(Fig. 2), whereas MitoVit E reported by Murphy and co-workers (24, 25) has 2 carbons in 
between.  
All the other chemicals used in this study were obtained from Sigma-Aldrich unless 
stated otherwise.  
Animals and diets.  
A total of sixty-four 7-week-old C57BL/6 male mice were purchased from the 
Jackson Laboratory (Bar Harbor, Me). Sixty-four mice were divided into four blocks and 
arrived at four different times because each time 16 mice at most could be handled for 
mitochondrial isolation and their subsequent assays, which had to be finished on ice within 9 
hours after animal dissection when freshly isolated mitochondria were still functional. 
Animals were housed one per cage in a temperature-controlled (18-22oC) and light-
controlled environment with a 12:12-h light-dark cycle. After being fed a high fat (HF) diet 
(35% fat, 36.1% carbohydrate, and 20.4% protein; TD03584; Harlan, see detailed 
composition in Table 1) for 5 weeks (including 1 week of acclimatization) to initiate some fat 
deposition and oxidative stress, each block of 16 mice were assigned randomly to one of four 
groups. Groups I and II were fed a low fat (LF) diet (70.8% carbohydrate, 4.6% fat, and 
16.4% protein; D12489B; Research Diets, see detailed composition in Table 2) and a 
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medium fat (MF) diet (56.7% carbohydrate, 15.6% fat, and 18.5% protein; D12266B; 
Research Diets, see detailed composition in Table 2), respectively, with each group gavaged 
with drug vehicle (0.9% NaCl solution). Groups III and IV were fed the same diet of Groups 
I and II, respectively, with each group gavaged 40 mg MitoVit E/kg body weight. Gavage 
was conducted every other day for 5 weeks. All mice had unrestricted access to feed and 
water. Body weight and feed intake were recorded for each mouse every week. Excreted 
urine was freshly collected for 3 consecutive days for each week and immediately frozen in -
80 oC for the subsequent analysis of urinary creatinine and epi-8 isoprostane. Mice were 
euthanized by CO2 inhalation followed by cardiac puncture from which blood samples were 
used for the determination of activities of superoxide dismutase (SOD) and glutathione 
peroxidase and concentration of triacylglycerol, non-esterified fatty acid (NEFA), and H2O2. 
Liver, gastrocnemius, white adipose tissues (inguinal and epididymal fat pads), and the rest 
of carcass excluding skin, feet, head, tail, and viscera were weighed. The whole 
gastrocnemius and about 0.5 g liver were immediately used for mitochondrial isolation and 
subsequent assays. The rest of liver, white adipose tissues, and gastrocnemius were frozen in 
liquid nitrogen and stored at -80 oC until for PCR assays. The rest of carcass was stored at -
20 oC for lipid and protein assays. The animal protocol was approved by the Institutional 
Animal Care and Use Committee of Iowa State University.  
Isolation of skeletal muscle mitochondria  
All procedures for skeletal mitochondrial isolation were conducted at 4 oC. 
Mitochondria were isolated from skeletal muscle according to Chappell and Perry with slight 
modification (28). Mice were killed, and gastrocnemius were rapidly excised and rinsed with 
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0.15 M iced KCl solution. Muscles were minced with scissors in Chappell-Perry Medium I 
(100 mM KCl, 50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 1 mM ATP, pH 7.2) and 
incubated in 20 volumes of Chappell-Perry Medium I supplemented with 0.15 mg/mL 
Nagarse (Sigma, St. Louis, MO) for 10 min. The muscles then were homogenized by using a 
Potter-Elvehjem glass homogenizer. After the homogenate was centrifuged at 600 × g for 10 
min, the supernatant was filtered through a double layer of cheesecloth and centrifuged at 14, 
000 × g for 10 min. The pellets were resuspended in modified Chappell-Perry II (100 mM 
KCl, 50 mM Tris-HCl, 1 mM MgCl2, 0.2 mM EDTA, 1 mM ATP, pH 7.2) with 0.5% bovine 
serum albumin (BSA) and centrifuged at 7,000 × g for 10 min. The pellets were resuspended 
in modified Chappell-Perry II without BSA and centrifuged at 3500 × g for 10 min (this step 
was repeated twice). The final mitochondrial pellets were ready for the subsequent H2O2, 
ATP, and aconitase assays. 
Isolation of liver mitochondria 
All procedures for liver mitochondrial isolation were conducted at 4 oC. Liver 
mitochondria were isolated according to Cawthon et al. with modification (29). Briefly, 
around 0.5 g of fresh liver was minced by scissors in 10 mL iced extraction buffer (10 mM 
HEPES, 200 mM mannitol, 70 mM sucrose, and 1 mM EGTA, pH 7.5). After 416.7 µL BSA 
(50 mg/ml) were added, the minced liver then was homogenized by using a Potter-Elvehjem 
glass homogenizer followed by centrifugation at 600 × g for 8 min. The supernatants were 
filtered through a double layer of cheesecloth before centrifuged at 11,000 × g for 12 min. 
The pellet was resuspended in 20 mL extraction buffer and centrifuged at 600 × g for 8 min. 
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Supernatants were centrifuged at 11, 000 × g for 12 min to get the mitochondrial pellets 
ready for the subsequent H2O2, ATP, and aconitase assays.  
Mitochondrial ATP production rate 
ATP production measurement is based on the reaction of ATP with firefly luciferase, 
providing a luminescence signal proportional to the concentration of ATP in the solution. 
Sample reaction was conducted in white Falcon 96-well microplates with a 100-µL reaction 
system (25 mM Tricine, 5 mM MgSO4, 0.1 mM EDTA, 0.1 mM NaN3, pH = 7.8) containing 
mitochondrial extract, substrates (GM, 1 mM glutamate plus 1 mM malate; GMP, 1 mM 
glutamate plus 1 mM malate plus 0.005 mM palmitoyl-L-carnitine; GMPK, 1 mM glutamate 
plus 1 mM malate plus 0.005 mM palmitoyl-L-carnitine plus 10 mM α-ketoglutarate), ADP 
(0.025 mM), and luciferase reagent (supplied in ATP Bioluminescence Assay Kit CLS II, Cat 
# 1699695, Roche). Blank contained all components in the above reaction system except 
without mitochondrial extract. Luminescence was detected by the SynergyTM 2 Multi-Mode 
microplate reader (BioTek Instruments, VT), and the results were analyzed by software Gen5 
(BioTek Instruments, VT). The integration time for each reading was set at 1 s, and the 
interval between readings at 36 s for a total of recording time of 6 min (11 readings). The 
slope of increase within the linear portion of the curve was used for the ATP production rate, 
and the slope of increase in the blank was subtracted from the slope of increase in the 
samples. ATP concentration was calculated on the basis of the values obtained from an ATP 
standard curve constructed by using ATP solutions containing 0, 0.01, 0.1, 1, 10, 100, and 
1000 nM ATP. The rate of mitochondrial ATP production was expressed as nanomole ATP 
per minute per milligram mitochondrial protein. 
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Mitochondrial H2O2 production rate 
Mitochondrial H2O2 production rate was measured by using AmplexTM Red-
horseradish peroxidase (N-acetyl-3,7-dihydroxyphenoxazine; Cat # A12222, Molecular 
Probes, Eugene, OR) as previously described by Muller et al. (30). Sample reaction was 
conducted in black Falcon 96-well microplates with a 100-µL reaction system (125 mM KCl, 
10 mM HEPES, 2 mM K2HPO4, 5 mM MgCl2) containing mitochondrial extract, substrates ± 
inhibitors (GM, 5 mM glutamate plus 5 mM malate; GM + rotenone, 5 mM glutamate plus 5 
mM malate + 10 µM rotenone; SUC, 9 mM succinate; SUC + antimycin, 9 mM succinate + 
10 µM antimycin), CuZnSOD (100 units/ml), AmplexTM Red Reagent (80µM), and 
horseradish peroxidase (1 unit/mL). Blank contained all components in the above reaction 
system except without mitochondrial extract. Fluorescence was followed at excitation 
wavelength of 530 nm and an emission at 590 nm on the SynergyTM 2 Multi-Mode 
microplate reader (BioTek Instruments, VT), and results were analyzed by software Gen5 
(BioTek Instruments, VT). The interval between readings was set at 36 s for a total of 
recording time of 10 min (23 readings). The slope of increase within the linear portion of the 
curve was used for the H2O2 production rate, and the slope of increase in the blank was 
subtracted from the slope of increase in the samples. H2O2 concentration was calculated 
based on the values obtained from an H2O2 standard curve constructed by using H2O2 
solutions containing 0, 0.125, 0.25, 0.3125, 0.5, 0.625, 1.25 µM H2O2. The rate of 
mitochondrial H2O2 production was expressed as nanomole H2O2 per minute per milligram 
mitochondrial protein. 
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Mitochondrial aconitase activity 
Aconitase activity is measured by measuring NADP+ reduction by citrate in the 
presence of isocitrate dehydrogenase (the conversion of citrate to isocitrate by aconitase 
being the rate-limiting step). A fluorometric measurement was recorded at the excitation 
wavelength of 355 nm and emission wavelength of 460 nm at 17-sec intervals for 10 min to 
quantify reduction of NADP+. Sample reaction was conducted in regular Falcon 96-well 
microplates with a 200-µL reaction system (50 mM Tris-HCl plus 0.6 mM MnCl2, pH 7.4) 
containing mitochondrial extract, NADP+ (0.2 mM), sodium citrate (5 mM), and pig heart 
isocitrate dehydrogenase (1 unit/mL). Slope of increase in NADPH fluorescence was used 
for aconitase activity and the slope of increase in the blank was subtracted from the slope of 
increase in the samples. The results were analyzed by software Gen5 (BioTek Instruments, 
VT) and expressed as fold change relative to the values of group fed low fat diet without 
drug set to 1 unit. 
Determination of protein carbonyls  
OxyBlot Protein Oxidation Detection Kit (Cat # S7150, Intergen, Purchase, NY) was 
used for detection of mitochondrial protein carbonyls. After denaturation, mitochondria 
protein was treated with DNPH before electrophoresis on 12% SDS-polyacrylamide gels. 
Standard Western blotting procedures were followed thereafter using primary and secondary 
antibodies supplied with the kit. Enhanced chemiluminescence detection reagents (Cat # 
RPN2132, Amersham Biosciences, Piscataway, NJ) were used to generate a 
chemiluminescent signal, and bands were visualized by using a 16-bit charge-coupled device 
camera (FluorChem8800; Alpha Innotech Corporation, San Leandro). Blots were analyzed 
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using ImageJ image analysis program developed at the National Institutes of Health. Optical 
density was determined by calculating the net optical density (sum of the background-
subtracted pixel values) of all the carbonylated bands within a given lane. 
Measurement of urinary isoprostane and creatinine 
 Urine samples were thawed at room temperature and vortexed vigorously before 
analysis. Urinary 8-epi-PGF2a was determined by using a commercially available ELISA kit 
from Oxford Biomedical Research (Cat # EA 85, Oxford, MI). Samples were analyzed in 
triplicates. Internal controls were run on every plate to adjust the plate differences. Urinary 
creatinine was quantified with a commercial kit from Cayman Chemical (Cat # 500701-96, 
Ann Arbor, MI) using a method based on the reaction of creatinine and alkaline picrate 
according to the manufacturer’s instruction. Results of urinary isoprostane were normalized 
by the urinary ceatinine. 
Measurement of plasma parameters 
Activities of plasma superoxide dismutase (Cat # 706002) and glutathione peroxidase 
(Cat # 703102) were measured by using kits from Cayman Chemical (Ann Arbor, MI). 
Plasma H2O2 concentration was measured using an Amplex Red hydrogen peroxide assay kit 
(Cat # A22188, Invitrogen). Plasma triacylglyerol was measured by using Triglyceride (GPO) 
(Liquid) Reagent Set (Cat # T7532-120, Pointe Scientific, Canton, MI). Plasma NEFA was 
measured using NEFA C kit (Cat # 994-75409, Wako, Richmond, VA). Activities of plasma 
superoxide dismutase and plasma glutathione peroxidase and concentration of plasma H2O2 
were expressed as fold change relative to the values of group fed low fat diet without drug set 
to 1 unit. 
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Measurement of mitochondrial size and number 
Eight mice from one block (2 mice/treatment) were selected for assay of 
mitochondrial size and number by transmission electron microscopy. Soleus muscle was 
excised from mice and immediately immersed in a cold (4oC) primary fixative consisting of 
2% glutaraldehyde and 2% paraformaldehyde in a 0.1 M cacodylate buffer at pH 7.24. The 
muscle was sliced into smaller pieces in the fixative and stored overnight at 4oC. The pieces 
were washed in cold buffer (3 times, 20 min each) and placed into 1% OsO4 in the same 
buffer for 1 h. After this secondary fixation, the pieces were washed several times in the 
buffer, placed into 2% aqueous uranyl acetate for 1 h and dehydrated through an ethanol 
series to pure ethanol and ultra-pure ethanol before infiltration with increasing concentrations 
of Embed 812 resin mixture to pure resin mixture. Pieces were embedded in molds and 
polymerized at 60oC for 24 h. The pieces were sectioned 1 µm thick with glass knives using 
a Leica-Reichert ultramicrotome (www.leica.com) to determine orientation and location. 
Thin sections 60-90 nm thick were cut with a diamond knife and placed on 200 mesh copper 
grids. Images were made using a JEOL 2100 TEM (www.jeol.com) at a set magnification 
(4000x) with a bar scale on each image. The images were transferred into an SIS Analysis 
(Olympus, www.soft-imaging.net) program that calculated mitochondrial number and 
individual area.  
Total lipid content in liver 
Total lipid concentration in liver was determined gravimetrically according to Folch et 
al. (31) with the following modifications. Liver tissue with wet weight between 250 and 300 
mg was homogenized in 10 mL of chloroform-methanol (2:1 vol/vol) in a 25- x 150-mm 
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screw-top extraction tube and sonicated for 30 s (model 350 Sonifier, Bronson Sonic Power 
Corp., Danbury, CT). Samples were shaken for 1 h (model 75 Wrist-Action Shaker, Burrel 
Scientific, Pittsburgh, PA), and 2 mL of 0.15 M NaCl was added. After mixing for 5 to 10 s, 
the mixture was centrifuged at 500 x g for 20 min (model K centrifuge, International 
Equipment Co., Needham Heights, MA), and the methanol-water layer was aspirated. The 
chloroform-containing fraction was filtered through a Buchner funnel and a 42.5-mm glass 
microfiber filter (Whatman International Ltd., Maidstone, UK) to a preweighed scintillation 
vial. Tubes were washed 3 times with 2, 4, and 4 mL of chloroform, respectively. The 
scintillation vials containing the total liver lipids were dried under constant airflow at 50°C 
for 2.5 h (SC/48R sampler concentrator, Brinkmann Instruments, Inc., Westbury, NY) and 
reweighed to calculate the total lipid content (% lipid= total lipid weight/liver sample weight 
× 100).  
Assay of candidate gene expression 
Adipose tissue and skeletal muscle total RNA was extracted by using TRIZOL 
reagent (Cat # 15596-026, Invitrogen, Carlsbad, CA) according to manufacture’s instructions. 
Liver total RNA was extracted by using an RNeasy Mini Kit (Cat # 74106, Qiagen, Valencia, 
CA) according to the manufacturer’s protocol. All the RNA samples further were treated 
with TURBO DNase (Cat # AM1907, Ambion, Austin, TX). The concentration of total RNA 
was estimated with the Nano1000 spectrophotometer (NanoDrop, Wilmington, DE, USA), 
and the integrity and size distribution of the purified RNA was determined by denaturing 
agarose gel electrophoresis and ethidium bromide staining. Prior to final qPCR sample 
analyses, a test plate was run (using a mixture of RNA samples serially diluted) for each 
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target of interest to identify 1) the specific RNA sample dilution range at which qPCR 
inhibition no longer existed and 2) the extended dilution range of the standard curves within 
which all targets exhibited amplification efficiencies between 80 and 100%. Test plate set-up 
parameters and analysis were performed using PREXCEL-Q (P-Q) (32). Subsequently, the 
optimally diluted RNA samples were used as “RNA templates” in 15 µL one-step real-time 
Qpcr reaction by using iScriptTM One-Step RT-PCR Kit with SYBR Green (Cat # 170-8893, 
Bio-Rad, Hercules, CA) on an iCycler real-time machine (Bio-Rad). After Ct values were 
collected, relative mRNA expression quantity for each qPCR target was calculated by using 
the equation: relative quantity= 10(Ct-b)/m where the slope (m) and y-intercept (b) were 
generated from each target’s standard curve. Housekeeping gene β-actin also was amplified 
from all the samples in parallel to normalize target genes. See Table 3 for primer sequences.  
Whole body lipid and protein contents  
Mice carcasses were ground and analyzed for lipid and protein content (AOAC, 
1996).  
Mitochondrial protein concentration  
Protein concentration was determined by using the Bradford method (33). 
Statistical analysis  
Data were analyzed by analysis of variance by using a general randomized complete 
block design with block considered the block. Block, diet, drug, and their interaction were 
the fixed effects in the model. SAS Proc Mixed (SAS, 2005), chosen because it provided 
conveniently formatted output, was used to compute the ANOVA table, least squares means 
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(LSMEANS), and differences between LSMEANS. The slopes of body weight gain over 
weeks (from week 6 to week 10) for all mice were calculated and then analyzed by using the 
above model. Differences between groups were considered to be significant at P < 0.05. 
Results 
Characteristics of mice during the first 4 weeks before treatment 
 Body weight increased significantly (P <0.05) when mice were fed the high fat diet 
(Fig. 3, A). Feed intake did not change after 2 weeks of high fat feeding and increased 
significantly for the second 2 weeks compared with that of the first 2 weeks (Fig. 3, B). 
Urinary isoprostane/creatinine increased 6-fold after 2 weeks of high fat feeding and then 
remained the same (Fig 3, C).  
Growth performance of mice after treatment  
Body weight and feed intake in all four groups dropped sharply for the first week 
because of the stressful gavage, but the mice quickly recovered after the first week after they 
got used to the gavage (Fig 4). Medium high fat diet significantly increased the body weigh 
gain in week 9 (P < 0.05) and still kept that tendency (P = 0.06) at week 10 (Fig. 4, A), 
whereas it significantly decreased the feed intake in week 7, 8 and 10 (Fig. 4, C). MitoVit E 
had a significantly inhibitory effect on body weight (P < 0.05) starting from week 8 until the 
end of this study (Fig. 4, B) although it had no effect on feed intake during the whole 
treatment period (Fig. 4, D). Medium fat diet significantly increased the slope of body weight 
gain from wk 6 to wk 10 (P < 0.0001), whereas MitoVit E significantly decreased the slope 
of body weight gain during the same period (P = 0.05).  
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Body composition  
Medium fat diet significantly increased the weight of both epididymal (P < 0.001) 
and inguinal (P < 0.001) fat pads (Table 4). MitoVit E significantly decreased the weight of 
liver (P < 0.05), and epididymal (P < 0.05) and inguinal (P < 0.05) fat pads (Table 4). In 
contrast, MitoVit E also significantly (P = 0.054) increased the weight of skeletal muscle 
(Table 4). No effect of diet or drug was seen on carcass weight (Table 4). Medium fat diet 
significantly increased the total liver lipid (P = 0.0527) and whole body fat content (P < 
0.05), whereas it significantly decreased the whole body protein content (Table 5). MitoVit E 
significantly decreased the total liver lipid (P < 0.05) and whole body fat content (P < 0.05) 
(Table 5) whereas it did not show any effect on whole body protein content (Table 5). 
Measurement of urinary isoprostane/creatinines  
A dramatic drop was seen in all the four treatments when mice were switched from 
high fat diet to either low fat diet or medium fat diet (Figure 5). Both low fat diet and 
MitoVit E significantly (P < 0.05) decreased the urinary isoprostane to creatinine ratio to a 
greater extent than medium fat diet and placebo groups, respectively, in all the weeks (weeks 
6, 7, 8, 9, and 10) (Fig. 5, A and B). In addition, urinary isoprostane to creatinine ratio 
remained almost unchanged for each treatment during weeks 6, 7, 8, 9, and 10 after the 
dramatic drop for the first week (week 5) (Figure 5). 
Measurement of plasma parameters 
 Medium fat diet tended to decrease concentration of plasma glutathione peroxides 
(GPx) (P = 0.058), whereas it significantly (P < 0.05) increased concentration of plasma 
hydrogen peroxide (H2O2) (Table 6). Although MitoVit E did not show any effect on both 
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plasma GPx and H2O2, it did significantly (P < 0.05) increase the activity of superoxide 
dismutase (SOD) (Table 6). Besides, there was an interaction between diet and drug on 
plasma SOD activity (P < 0.05). Finally, no effect of diet or drug was seen on either 
triacylglycerol (TAG) or non-esterified fatty acid (NEFA) (Table 6). 
Measurement of mitochondrial metabolites in liver  
ATP production rate was higher when GMP (glutamate + malate + palmitoyl L-
carnitine + α-ketoglutarate) were substrates than that when GM (glutamate + malate) were 
substrates, indicating that addition of palmitoyl L-carnitine increased hepatic mitochondrial 
ATP production rate (Table 7). In contrast, GMPK (glutamate + malate + palmitoyl L-
carnitine + α-ketoglutarate) substrates decreased ATP production rate in comparison with 
GMP substrates, indicating that addition of α-ketoglutarate inhibited mitochondrial ATP 
production rate in liver (Table 7). MitoVit E significantly (P < 0.05) increased hepatic 
mitochondrial ATP production when GMP and GMPK but not GM were used as the 
substrates, whereas medium fat diet showed no effect regardless of the substrates (Table 7). 
Addition of inhibitors rotenone and antimycin slightly decreased hepatic 
mitochondrial H2O2 production rates compared with GM (glutamate + malate) and SUC 
(succinate), respectively (Table 8). Medium fat diet significantly (P < 0.05) increased hepatic 
mitochondrial H2O2 production rate when GM and GM+ rotenone (glutamate + malate + 
rotenone) were substrates (Table 8). In contrast, MitVit E significantly (P < 0.05) decreased 
their H2O2 production under conditions of these two substrate combinations (Table 8). No 
effect of diet or drug was seen when either SUC or SUC + antimycin (succinate + antimycin) 
served as the substrates (Table 8).  
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MitoVit E significantly (P < 0.05) increased the hepatic mitochondrial aconitase 
activity, whereas medium fat diet did not affect hepatic aconitase activity (Table 9). 
Consistently, MitoVit E significantly (P < 0.05) inhibited protein oxidation as indicated by 
the concentration of protein carbonyl, whereas no effect of medium fat diet was seen (Table 
9). In Fig. 6 (A), representative immunoblots of hepatic protein carbonyl were shown.   
Measurement of mitochondrial metabolites in skeletal muscle 
Consistent with the observation in hepatic mitochondria, mitochondrial ATP 
production rate in skeletal muscle was higher when GMP were substrates than that when GM 
were substrates, whereas GMPK substrates decreased ATP production rate in comparison 
with GMP substrates, indicating that addition of palmitoyl L-carnitine increased 
mitochondrial ATP production rate while addition of α-ketoglutarate inhibited mitochondrial 
ATP production rate in muscle (Table 10). Neither diet or MitoVit E has an effect on 
mitochondrial ATP production rate in the muscle regardless of the substrate combinations 
(Table 10).  
Addition of inhibitors rotenone and antimycin dramatically increased mitochondrial 
H2O2 production rates in muscle when compared with GM (glutamate + malate) and SUC 
(succinate) as alone, respectively (Table 11).Medium fat diet significantly increased 
mitochondrial H2O2 production rate in muscle only when GM were the substrates (P < 0.05), 
whereas no effect of MitoVit E was seen for regardless of the substrate combinations (Table 
11). 
 In addition, medium fat significantly (P < 0.05) decreased the mitochondrial 
aconitase activity in skeletal muscle, whereas no effect of MitoVit E was seen (Table 12). 
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Consistently, medium fat diet but not MitoVit E significantly (P < 0.05) increased the protein 
oxidation as indicated by the concentration of protein carbonyl (Table 12). In Fig. 6 (B), 
representative immunoblots of protein carbonyl in muscle were shown. 
Measurement of mitochondrial number and size in the soleus muscle  
The transmission electron microscopy study demonstrated the effects of medium fat 
diet and MitoVit E on the mitochondrial density in the soleus muscle. Medium fat 
significantly decreased both intermyofibrillar (P < 0.05) and subsarcolemmal (P < 0.001) 
mitochondria numbers, whereas MitoVit E significantly (P < 0.05) increased the number and 
the average size of subsarcolemmal mitochondria, but not the intermyofibrillar mitochondria 
(Table 13). Specifically, the effect of MitoVit E on the density of subsarcolemmal 
mitochondria was attributed to its effect in medium fat diet but not in low fat diet (Table 13). 
Besides, there was an effect of interaction between diet and MitoVit E on the number of 
subsarcolemmal mitochondria (P <0.05). Shown in Fig. 7 is the mitochondrial density 
assessed by transmission electron microscopy. The density of subsarcolemmal mitochondria 
was much higher than that of intermyofibrillar mitochondra except in medium fat diet 
without MitoVit E group where hardly could mitochondria be observed in either 
intermyofibrillar or subsarsarcolemmal areas (Fig. 7).  
Expression of genes involved in energy and lipid metabolism.  
To clarify the mechanisms involved in the effects of medium fat diet and MitoVit E 
on lipid deposition in liver and white adipose tissues, we measured the mRNA abundances of 
genes implicated in energy and lipid metabolism. Medium fat diet significantly decreased 
fatty acid synthase (FAS) (P < 0.05) and acetyl-CoA carboxylase (ACC) (P < 0.05) in both 
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liver and adipose tissue and peroxisome proliferator-activated receptorγ (PPARγ) (P = 0.04) 
only in adipose tissue (Table 14 and 15). In contrast, PPARγ in liver (P < 0.001) was 
significantly upregulated by medium fat diet (Table 14). In addition, none of these genes was 
affected by MitoVit E (Table 14 and 15). Medium fat significantly (P = 0.015) decreased 
hormone-sensitive lipase (HSL) in adipose tissue (Table 16). Neither diet or MitoVit E had 
effect on the gene expression of lipoprotein lipase (LPL) in adipose tissue, and PPARγ 
coactivator 1 α (PGC1α), carnitine palmitoyl transferase 1 b (CPT1b) and uncoupling protein 
3 (UCP3) in muscle (Table 16 and 17). MitoVit E significantly increased gene expression of 
uncoupling protein 2 (UCP2) in adipose tissue (P = 0.004) and acyl-CoA oxidase (ACO) in 
both liver (P < 0.049) and adipose tissue (P = 0.007) whereas effect of medium fat diet was 
not involved in these genes (Table 14, 15, and 16). Consistently, MitoVit E also increased the 
ACO expression in muscle, even though it did not reach statistical significance (P = 0.06) 
(Table 17). Medium fat diet tended to increase carnitine palmitoyl transferase 1 a (CPT1a) (P 
= 0.06) but meanwhile to decrease ACO (P = 0.08) in adipose tissue (Table 15). 
Discussion 
Cumulative evidence strongly suggests that elevated oxidative stress is associated 
with obesity development (10-12, 14-16). This suggestion has also been confirmed by our 
observation that urinary isoprostane (biomarker of oxidative stress) increased with obesity 
development during the first 4 weeks of high fat feeding (Figure 3, A and C). Oxidative 
stress is more accepted as a consequence of obesity than a cause because it is believed that 
obesity per se may induce systemic oxidative stress at first stage and that increased oxidative 
stress in accumulated lipid is one of the underlying causes of obesity-associated metabolic 
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syndrome (16). However, there is growing evidence that oxidative stress might be more a 
parallel process than a consequence and consequently should be a major component of a 
vicious cycle of events (34, 35). Therefore, in order to initiate this vicious cycle, mechanisms 
of oxidative stress as a cause of obesity must exist. To our knowledge, very few in vivo 
studies, to date, have proposed that oxidative stress could contribute to obesity development. 
The fact that mitochondrial aconitase is particularly susceptible to oxidative damage (1) and 
oxidative inactivation of aconitase can deteriorate the oxidative injury (2) led us to speculate 
that aconitase inhibition could be an important mediator in the propagation stage of oxidative 
stress leading to obesity. However, it was not until the proposal of “aconitase inhibition 
cascade” by Wlodek and Gonzales (3) that our central hypothesis was established that 
oxidative stress might contribute to obesity development mediated by aconitase inhibition. 
This notion that aconitase inhibition cascade induced by oxidative stress leads to obesity is 
not without precedent. In fact, aconitase inhibition induced by oxidative stress also has been 
proposed to be one of the mechanisms contributing to ageing (1) and Parkinson’s Disease 
(36). On the basis of our central hypothesis, we further proposed that MitoVit E, a 
mitochondrially targeted antioxidant, can decrease obesity development by alleviating 
mitochondrial oxidative stress, reactivating aconitase activity, and consequently reversing its 
inhibition cascade. Although mitochondrially targeted antioxidants have shown effective 
protection against oxidative damage in a large range of mitochondrial and cell models (26, 27, 
37-42), their application in animal and clinical studies are lacking. Moreover, effect of 
mitochondrially targeted antioxidants on obesity development has never been studied in vivo 
so far. Here, we investigated the growth performance, body composition, mitochondrial 
density and function, antioxidant defense system, oxidative stress status, and lipid and energy 
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metabolism of the C57BL/6 mice after they were switched from 5 weeks of high fat feeding 
to either medium fat diet or low fat diet and with or without MitoVit E. The purpose of this 
experimental design was 1) to initiate a vicious cycle of obesity development and high 
oxidative stress at the first stage for C57BL/6 mice fed high fat diet for the first 5 weeks and 
then 2) to move on to the second stage to investigate whether MitoVit E can break that 
vicious cycle and alleviate both oxidative stress and obesity. This experimental design 
derives from the idea that “oxidative stress is a major component of a vicious cycle leading to 
many diseases, thus much effort is devoted to developing rational drug or genetic therapy 
targeted at the ‘oxidative stress component’ to block that vicious cycle” (34).  
Within our expectation, the body weight gain of medium fat diet groups rebounded 
faster than the low fat diet groups after being switched from high fat diet and getting used to 
stressful gavage (Fig. 4 A). Medium fat diet also decreased the feed intake (Fig. 4 C) because 
it had higher caloric density (4.41 kcal/g) than did low fat diet (3.90 kcal/g). We found that 
MitoVit E significantly decreased the growth rate from wk 6 to wk 10 and also inhibited the 
body weight gain for the last 3 weeks (Fig. 4, B), and furthermore, this was not achieved by 
increasing the calorie intake because no effect of MitoVit E on the feed intake was seen (Fig. 
4, D). The inhibitory effect of MitoVit E on body weight gain could be attributed to its 
inhibitory effect on weights of liver and white adipose tissues (Table 4) and whole body fat 
content (Table 5). Furthermore, the decrease of liver weight by MitoVit E can be further 
explained by its inhibitory effect on total liver lipid content (Table 5). In contrast, MitoVit E 
enhanced muscle mass (Table 4). This reciprocal regulation of adipose and muscle mass by 
MitoVit E recalled us the role of interleukin 15 (IL-15), a cytokine highly expressed in 
skeletal muscle, which can reduce fat deposition without altering food intake and suppress fat 
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gain in growing rats (43, 44) while protecting muscle protein from degradation in 
degenerative conditions such as cachexia (45). It is suggested that IL-15, as a promising 
molecule in the treatment of human obesity, might be involved in a muscle-fat endocrine axis 
and may regulate energy use between the two tissues (46). Consistently, this reciprocal 
regulation of adipose and muscle mass also has been reported in another anti-obesity therapy, 
high dietary calcium, which can suppress fat gain while protecting muscle mass in diet-
induced obesity (47). Therefore, like high dietary calcium, MitoVit E also may regulate 
energy partitioning by modulating IL-15 and other cytokines in both adipose tissue and 
skeletal muscle, thereby favoring elevated energy expenditure in adipose tissue and 
preserving energy storage in skeletal muscle (47). Future work in our laboratory will 
investigate the role of MitoVit E in regulating IL-15 and other cytokines involved in this 
muscle-fat endocrine axis. 
The isoprostanes are a unique series of prostaglandin-like compounds formed in vivo 
from the free radical-catalyzed peroxidation of arachidonic acid independent of the 
cyclooxygenase enzyme (48). The generation and secretion of isoprostane into the urine 
(normalized by urinary creatinine) is one of the most reliable approaches to assess oxidative 
stress status in vivo (49). Our data indicated urinary isoprostane increased with the obesity 
development during the first 5 weeks when mice were fed high fat diet (Fig. 3 C). The 
urinary isoprostane concentrationl after 2 weeks of high feeding was as six-fold high as 
before (Fig. 3 C). This result is very consistent with another finding (49) that ob/ob mice had 
up to a six-fold increase in 24-h isoprostane compared with that in controls. MitoVit E had 
the ability to normalize the high concentration of urinary isoprostane induced by medium fat 
diet (Fig. 5 A and B). However, untargeted vitamin E supplementation failed to decrease the 
            
 
70
urinary isoprostanes in either lean or obese mice (50). The authors (50) concluded that 
vitamin E supplementation is not sufficient to reduce extreme elevations in systemic 
oxidative stress due to hyperlipidemia and obesity. The discrepancy between their study (50) 
and our study indicates that MitoVit E can accumulate within mitochondria more effectively 
and therefore more effectively protect mitochondria from oxidative damage than untargeted 
vitamin E. In contrast, the inhibitory effect of MitoVit E on plasma H2O2 concentration was 
not seen (Table 6) indicating that different biomarkers of oxidative stress responded 
differently to antioxidant therapy. However, medium fat diet significantly increased plasma 
H2O2 concentration (Table 6), which is consistent with the finding of Bonnard et al. (19) that 
plasma H2O2 concentration was significantly elevated after 16 weeks of high fat/high sucrose 
feeding. Like different biomarkers of oxidative stress, antioxidant defense members, such as 
superoxide dismutase (SOD) and glutathione peroxidase (GPx), also responded differently to 
both effects of medium fat and MitoVit E (Table 6). In our study, MitoVit E increased the 
activity of plasma SOD but had no effect on plasma Gpx, whereas medium fat decreased the 
activity of plasma GPx but with no effect on plasma SOD (Table 6). This complexity also 
has been seen elsewhere (20), but specific mechanisms behind that effect are not exactly 
clear. It might relate to the fact that different diets or exogenous antioxidants have different 
capacity to regulate different endogenous antioxidants and oxidants. A good example is that 
N-acetylcysteine can provide cysteine supply, which is rate limiting for glutathione reduced 
form (GSH) synthesis, and therefore it can better increase GSH or GSH/GSSG (GSSG, 
glutathione oxidized form) than other antioxidants.  
Different combinations of substrates and inhibitors specific for distinct segments of 
the respiratory chain were used in this study to determine the sites of oxygen radical 
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generation in functional mitochondria. The details of these methods were nicely described by 
Barja (51). Specifically, an increase in oxygen radical production following the addition of 
an inhibitor means that the oxygen radical generation site is located in the carrier upstream 
from the site of inhibition, whereas a decrease in oxygen radical production following the 
addition of an inhibitor indicates that the generator must be situated downstream the site of 
inhibition (51). For example, the higher oxygen radical production observed in the presence 
than in the absence of rotenone in pyruvate/malate-supplemented rat mitochondria indicates 
that they produce ROS at Complex I because this is the only Complex situated on the 
substrate side of the inhibitor in this experiment (52). Similarly, the classically described 
increase in H2O2 production after addition of antimycin A to succinate-supplemented rat 
heart mitochondria is due to their capacity to produce ROS at Complex III (53, 54)(23,24). In 
our study, we found that addition of rotenone and antimycin to glutamate/malate-
supplemented and succinate-supplemented mice mitochondria, respectively, resulted in no 
increase in H2O2 production (Table 8). This result indicates that Complexes I and III are not 
the sources of ROS generation based on the above theory. This observation in our study 
conflicts with previous reports that liver mitochondria in immature (9-week-old) rats produce 
ROS at Complex I, II, and III (55) whereas in old mature rats (24-month-old) only Complex I 
and III are the free radical generators (56). Although different animals (rats vs. mice) and 
different techniques to detect H2O2 (homovanillic acid vs. Amplex Red) were used, these can 
very unlikely contribute to the difference of ROS generation site, which therefore still can 
not be explained. However, in the muscle, addition of rotenone and antimycin to 
glutamate/malate-supplemented and succinate-supplemented mice mitochondria resulted in 
approximately 4-fold and 6-fold increase in H2O2 production (Table 11), indicating that 
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Complex I and III are the sources of ROS generation, which is consistent with previous 
finding (57).   
As to the effects of medium fat and MitoVit E on mitochondrial metabolites, there 
was a tissue-specific difference between muscle and liver. In the muscle, medium fat diet 
increased mitochondrial H202 production (Table 11), which inactivated aconitase (Table 12) 
and also increased protein carbonyl contents (product of oxidized protein) (Table 12). 
However, surprisingly, no effect of MitoVit E on the above mitochondrial metabolites was 
seen in the muscle (Tables 11 and 12). In contrast, in the liver, MitoVit E successfully 
normalized the increase of H2O2 production induced by medium fat diet (Table 8). Therefore, 
MitoVit E decreased the hepatic mitochondrial protein carbonyl content (Table 9), increased 
the aconitase activity (Table 9) and normalized the TCA cycle with an increase in ATP 
production (Table 7). The question arises why muscle is more resistant to an effect of 
MitoVit E compared to liver? Does it have to with the different MitoVit E uptake in liver and 
muscle? Smith et al (24) reported that when MitoVit E was fed in drinking water (similar to 
our gavage administration via intestinal absorption), MitoVit E uptake in the liver was about 
8 nmol/g wet weight. We could have made comparison if they also reported MitoVit E 
uptake in the muscle. However, they did report that the uptake of MitoQ in both liver and 
muscle were approximately 700 and 350 pmol/g wet weight respectively (24), indicating that 
uptake of MitoVit E in liver could be also much higher than that in muscle. Another 
possibility is that MitoVit E might have both effects on decreasing ROS production and 
antioxidant defense members in the muscle and therefore the net result is that MitoVit E has 
little effect on H2O2 production rate. The effect of MitoVit E on antioxidant defense 
members in muscle needs to be studied in the future.  
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Another impressive observation for the mitochondrial metabolites is the consistency 
between the aconitase activity and protein carbonyl content in both liver and muscle. It was 
very intriguing to find that the rankings of aconitase activity among these four treatment 
groups exactly reciprocally corresponds to their rankings of protein carbonyl content in both 
liver and muscle (Tables 9 and 12). This result agrees with the report that aconitase is very 
sensitive to oxidative damage (1) and therefore a very sensitive biomarker of oxidative stress 
(58). Therefore, this observation is understandable because a higher aconitase activity 
corresponds to a lower oxidative stress, which results in lower protein carbonyl content.  
As impressive as the above consistency is the inconsistency between H2O2 production 
and ATP production. Medium fat diet increased the mitochodrial H2O2 production in both 
liver and muscle (Tables 8 and 11). However, medium fat diet did not cause a decrease in the 
ATP production as we expected (Tables 7 and 10). This inconsistency also has been seen in 
caloric restriction for studying aging. Caloric restriction has been shown to decrease the 
production of ROS and reduce oxidative stress with increased age (55, 59, 60). However, it 
was found that caloric restriction had no effect on mitochondrial ATP production in liver 
(61), brain (61), muscle (62, 63), and heart (62).  
In addition, the capacity of mitochondria to use different substrates can be revealed 
by comparing their ATP production rates with different combinations of these substrates in 
our study. In both liver and muscle, mitochondrial ATP production rate with GMP 
(glutamate + malate + palmitoyl L-carnitine) as substrates is higher than that when GM 
(glutamate + malate) were the substrates (Tables 7 and 10), confirming that fatty acids can be 
well used by mitochondria via beta-oxidation for ATP production. Furthermore, in liver, the 
effect of MitoVit E on increasing ATP production rate with GMP as substrates but not with 
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GM (Table 7) further implies that MitoVit E can enhance the capacity of hepatic 
mitochondria to use fatty acids via beta-oxidation for ATP production, which supports our 
finding that gene expression of CPT1a (carnitine palmitoyl transferase 1 a) in liver was 
enhanced by MitoVit E (Table 14).  
Medium fat diet decreased the number and size of both subsarcolemmal and 
intermyofibrillar mitochondria in soleus (Table 13), which also were seen in the 
gastrocnemius of C57BL/6 mice fed high fat/high sucrose diet (19). Our observation that 
MitoVit E had the ability to normalize the decrease of number in subsarcolemmal 
mitochondria induced by medium fat diet also was proven by Bonnard et al. (19) who 
reported that another antioxidant N-acetylcysteine restored the mitochondrial density, which 
was altered by the steptozotocin-induced oxidative stress. Then a question arises: why did 
MitoVit E have no effect on mitochondrial H2O2 production rate in the gastrocnemius but it 
could normalize the decrease of subsarcolemmal mitochondrial density in soleus induced by 
medium fat diet? Could MitoVit E restore the altered subsarcolemmal mitochondrial density 
by some other unknown properties other than as an antioxidant? There is such possibility. In 
addition, this question also could have to do with the different fiber types in two muscles (red 
oxidative soleus vs. white glycolytic gastrocnemius)? The precise mechanism still remains 
elusive. We chose soleus instead of gastrocnemius for microscopy because microscropy 
needs only a very tiny sample and the size of soleus is perfect. The big variance of sampling 
from gastrocnemius could be a big problem for us considering that only two replicates in 
each treatment were used for microscropy. 
To explore the mechanisms involved in the reduction of liver lipid content and weight 
of inguinal and epididymal fat pads by MitoVit E, quantitative RT-PCR was used to measure 
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the mRNA levels of genes implicated in lipid metabolism in liver, white adipose tissues, and 
muscle. Based on our hypothesis that MitoVit E might improve obesity development by 
reducing mitochondrial oxidative stress and subsequently reversing the “aconitase inhibition 
cascade”, we expect to see that MitoVit E would decrease lipogenesis and increase 
mitochondrial fatty acid oxidation and feed intake by normalizing mitochondrial ATP 
production, alleviating cytosolic citrate accumulation, and decreasing ACC and malonyl CoA. 
However, unexpectedly, we found 1) ACC and FAS expressions in both liver (Table 14) and 
white adipose tissue (Table 15) were unaffected by MitoVit E; 2) MitoVit E increased 
mitochondrial ATP production rate in liver (Table 7) but it did not affect feed intake as we 
expected (Fig. 4 D); 3) MitoVit E enhanced beta-oxidation by enhancing CPT1a expression 
in the liver, which, however, was not mediated by the decrease of ACC and malonyl CoA as 
we hypothesized (Table 14). Another unexpected but compelling observation is that MitoVit 
E increased peroxisomal fatty acid oxidation in liver (Table 14), white adipose tissue (Table 
15), and muscle (Table 17). Additionally, MitoVit E might also play a role in improving the 
anti-oxidant defense system mediated by mild activation of UCPs (uncoupling proteins) 
because MitoVit E was found in this study to increase UCP2 in adipose tissue (Table 16), 
which contributed to a dissipation of proton gradient and potential across inner mitochondrial 
membrane and therefore a resultant decrease of ROS production. Consistently, high dietary 
calcium as another anti-obesity therapy increased UCP2 expression in adipose tissue and 
UCP3 expression in skeletal muscle, which also were associated with decreased ROS 
production (64)(187). However, we found in our study that UCP3 expression in skeletal 
muscle was affected by neither medium fat diet nor MitoVit E (Table 17). 
      The effect of MitoVit E on mitochondrial oxidative stress in adipose tissue has not been 
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investigated because of the difficulty of mitochondrial isolation from adipose tissue. 
However, in both liver and adipose tissue, the fact that MitoVit E did not affect those genes 
(PPARγ, ACC, and FAS) in lipogenesis (Tables 14 and 15) and medium fat instead 
decreased the expression of these genes (Tables 14 and 15) reveals that “aconitase inhibition 
cascade” was not correct or just partially correct considering that MitoVit E did decrease 
mitochondrial oxidative stress in liver by increasing aconitase activity and decreasing protein 
carbonyl contents. The unsuccessful accumulation of cytosolic citrate when mitochondrial 
aconitase is inhibited by ROS could possibly explain that the alleviation of ROS-induced 
aconitase inhibition by MitoVit E failed to affect those cytosolic genes involved in 
lipogenesis. This possibility does exist because mitochondrial citrate could bind to the labile 
iron released from Fe-S cluster as a low-molecular -weight iron chelator when aconitase is 
oxidized by ROS (36) and be trapped within the mitochondria, instead of being transferred to 
cytosol for turning on the lipogenesis. Unfortunately, in our study we did not evaluate the 
concentration of cytosolic citrate, which should be considered in the future study. It was not 
surprising that medium fat diet decreased all these genes (PPARγ in adipose tissue, ACC and 
FAS in liver and adipose tissue) involved in lipogenesis (Tables 14 and 15) because the 
body’s need for fat can be supplied by medium fat diet without a need to initiating de novo 
lipogenesis. However, LPL in adipose tissue (a rate-limiting enzyme for deposition of serum 
triacylglycerol in adipose tissue) was not affected by either medium fat diet or MitoVit E 
(Table 16). In the response of adipose tissue to medium fat diet, it was very intriguing to find 
that ACO involved in peroxisomal fatty acid oxidation (Table 15) and HSL in lipolysis 
(Table 16) decreased, whereas CPT1b in mitochondrial fatty acid oxidation (Table 15) 
increased, indicating that the inhibitory effect of medium fat diet on peroxisomal fatty acid 
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oxidation and lipolysis overwhelms its stimulative effect on mitochondrial beta-oxidation to 
contribute to more fat deposition in medium fat diet. 
Therefore, all the evidence shown above suggests that MitoVit E could be potentially 
developed as an anti-obesity therapy. However, to develop MitoVit E as a pharmaceutical, 
the nonspecific toxicity of alkyTPP cations has to be addressed. Studies have shown that the 
extensive accumulation of lipophilic cations within isolated mitochondria can disrupt 
membrane integrity, respiration, and ATP synthesis (65-67). These negative effects of 
lipophilic cations on mitochondrial function will always limit the amounts of TPP-derived 
targeted antioxidants that can be used, and therefore it is essential that the compounds are 
effective antioxidants at concentrations well below those that disrupt function (25). Therefore, 
it has to be clarified that the decrease of fat deposition by MitoVit E found in our study does 
not derive from the toxicity of MitoVit E. We provide the following evidence to substantiate 
our claim that inhibition of fat deposition by MitoVit E is beneficial and not attributed to 
toxicity of MitoVit E : 1) the dosage we used in our study (20 mg/kg body weight per day) is 
far below the reported maxiumal tolerated dosage in drinking water fed to mice (60.4 ± 5.3 
mg/kg body weight per day) by Smith et al. (24); 2) we did not observe any physical signs of 
sickness for all the mice during the study; 3) unaffected feed intake during the whole study 
after MitoVit E administration excludes the possibility that mice were sick because of 
MitoVit E toxicity; 4) the mechanism of toxicity of TPP cations is to disrupt membrane 
potential and therefore inhibit ATP production. We, however, found in our study that 
MitoVit E does not affect ATP production rate in muscle and instead increased ATP 
production rate in the liver. 
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Conclusion 
This study showed that MitoVit E is an effective antioxidant by reducing systemic 
oxidative stress indicated by the decrease of urinary isoprostane/creatinine. MitoVit E acts in 
a tissue-specific manner to reduce the mitochondrial oxidative stress with higher efficacy in 
liver than in muscle, which might be attributed to their different uptakes. MitoVit E plays a 
role in energy partitioning by favoring elevated energy expenditure in adipose tissue and 
preserving energy storage in skeletal muscle. MitoVit E increases size and number of 
subsarcolemmal mitochondrial in the soleus, indicating its enhanced capacity of beta 
oxidation. MitoVit E decreases fat deposition in liver and white adipose tissue not by 
reversing “aconitase inhibition cascade” as we proposed, instead, through enhancing 
peroxisomal (in liver and adipose tissue) and mitochondrial (in liver) fatty acid oxidation. 
Unsuccessful accumulation of cytosolic citrate when aconitase is oxidized by ROS might 
explain the failure of our hypothesis of “aconitase inhibition cascade”. Finally, the possibility 
that inhibition of fat deposition in liver and adipose tissue derives from toxicity of MitoVit E 
also has been excluded. Taken together, all the evidence shown above indicates that MitoVit 
E merits additional research as an anti-obesity agent. 
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Table 1 Composition of high fat diet1 
Ingredient  Composition, % 
Casein 230.0 
DL-Methionine 3.5 
Sucrose 150.0 
Maltodextrin 191.35 
Lard 350.0 
Mineral Mix, AIN-93G-MX (94046)2 50.0 
Calcium phosphate, monobasic, monohydrate 2.5 
Vitamin Mix, AIN-93-VX (94047)3 18.4 
Choline bitartrate 
Total 
4.25 
1000 
1 Containing 36.1% carbohydrate, 35.2% fat, and 20.4% protein on an as-fed basis.  
2 100 g of mineral premix contained 10 g Ca; 3.12 g P; 7.2 g K; 2.04 g Na; 3.14 g Cl; 0.6 g S; 
0.4 mg I; 70 mg Fe; 1.01 g Mg; 60 mg Zn; 12 mg Cu; 20 mg Mn; 0.3 mg Mo; 0.3 mg Se; 2 
mg Cr; 10 mg Si; 2 mg F; 1 mg Ni; 1 mg B; 0.2 mg Li; and 0.2 mg V. 
3 100 g of vitamin premix contained 27.17 mg thiamin; 32.61 mg riboflavin; 32.61 mg 
pyridoxine; 163.04 mg nicotinic acid; 81.52 mg pantothenate; 10.87 mg folic acid; 4.08 mg 
phylloquinone; 1.09 mg biotin; 0.14 mg cyanocobalamin; 21,739 IU all-trans-retinyl 
palmitate; 408 IU all-rac-α-tocopheryl acetate; and 5,435 IU cholecalciferol. 
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Table 2 Composition of low fat and medium fat diets 
 LF diet1 MF diet2 
Ingredient gram kcal gram kcal 
Casein, 80 Mesh 190 760 190 760 
DL-Methionine 3 12 3 12 
Corn starch 498.5 1994 215 860 
Maltodextrin 10 35 140 75 300 
Sucrose 290 1160 290 1160 
Cellulose, BW200 30 0 30 0 
Butter fat 14.7 132.3 44.2 397.8 
Corn oil 39.3 353.7 118 1062 
Mineral Mix S100013 40 0 40 0 
Calcium carbonate 5.5 0 5.5 0 
Sodium chloride 5.5 0 5.5 0 
Potassium citrate, 1 H2O 13.5 0 13.5 0 
Vitamin Mix V100014 11 44 11 44 
Choline bitartrate 2 0 2 0 
FD&C Yellow dye #5 0.1 0 0 0 
FD&C Red dye #40 0 0 0.1 0 
Total 1178.1 4596 1042.8 4595.8 
1 Containing 70.8% carbohydrate, 4.6% fat, and 16.4% protein on an as-fed basis. 
2 Containing 56.7% carbohydrate, 15.6% fat, and 18.5% protein on an as-fed basis. 
3 100 g of mineral premix contained 14.9 g Ca, 11.4 g P, 1.4 g Mg, 10.3 g K, 0.9 g S, 2.9 g 
Na, 4.6 g Cl, 5.7 mg Cr, 17.1 mg Cu, 0.6 mg I, 128.6 mg Fe, 168.6 mg Mn, 0.5 mg Se, and 
82.9 mg Zn.  
4 100 g of vitamin premix contained 40,000 IU vitamin A, 10,000 IU vitamin D3, 500 IU 
vitamin E, 5 mg menadione sodium bisulfite (62.5% menadione), 2 mg biotin (1%), 100 µg 
cyancocobalamin (0.1%), 20 mg folic acid, 300 mg nicotinic acid, 160 mg calcium 
pantothenate, 70 mg pyridoxine·HCl, 60 mg riboflavin, and 60 mg thiamin·HCl. 
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Table 3 Sequences of primers used for real-time PCR1 
Genes Forward primers Reverse primers 
PPARγ 5’-ACATAAAGTCCTTCCCGCTGACCA-3’ 5’-AAATTCGGATGGCCACCTCTTTGC-3’ 
FAS 5’-TATCCTGCTGTCCAACCTCAGCAA-3’ 5’-TCACGAGGTCATGCTTTAGCACCT-3’ 
ACCα 5’-TAACAGAATCGACACTGGCTGGCT-3’ 5’-ATGCTGTTCCTCAGGCTCACATCT-3’ 
AOX 5’-TGCCTTTGTTGTCCCTATCCGTGA-3’ 5’-TTACATACGTGCCGTCAGGCTTCA-3’ 
CPT1a 5’-AGACCGTGAGGAACTCAAACCCAT-3’ 5’-CACAACAATGTGCCTGCTGTCCTT-3’ 
CPT1b 5’-TCAAGGTTTGGCTCTATGAGGGCT-3’ 5’-TCCAGGGACATCTTGTTCTTGCCA-3’ 
LPL 5’-ATGGATGGACGGTGACAGGAATGT-3’ 5’-TGGATAATGTTGCTGGGCCCGATA-3’ 
HSL 5’-TGTGGCACAGACCTCTAAATCCCA-3’ 5’-TCTCCAGTTGAACCAAGCAGGTCA-3’ 
UCP2 5’-AAGCAGTTCTACACCAAGGGCTCA-3’ 5’-TCTCGTGCAATGGTCTTGTAGGCT-3’ 
UCP3 5’-AACAGCTGCTCTTCTGCCTTCTCT-3’ 5’-TTGGAAGTTGGTCCTGTGCTTTGC-3’ 
PGC1α 5’-AGCACTCAGAACCATGCAGCAAAC-3’ 5’-TTTGGTGTGAGGAGGGTCATCGTT-3’ 
β-actin 5’-GGGTCAGAAGGACTCCTATG-3’ 5’-GTAACAATGCCATGTTCAAT-3’ 
1 PPARγ: peroxisome proliferator-activated receptorγ; FAS: fatty acid synthase; ACCα: 
acetyl-CoA carboxylase α; ACO: acyl-CoA oxidase; CPT1 a & b: carnitine palmitoyl 
transferase 1 a and b; LPL: lipoprotein lipase; HSL: hormone-sensitive lipase; UCP2 & 3: 
uncoupling protein 2 and 3; PGC1α: PPARγ coactivator 1α.  
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Table 4 Organ weights1 
Treatments Liver               (g) 
Inguinal fat       
(g)  
Epididymal fat      
(g) 
Muscle          
(g) 
Carcass2        
(g) 
LF + placebo 1.290 ± 0.039a 0.642 ± 0.036ab 0.940 ± 0.044bc 0.315 ± 0.007 11.240 ± 0.159 
MF + placebo 1.217 ± 0.035b 0.805 ± 0.056 c 1.218 ± 0.078a 0.308 ± 0.011 11.540 ± 0.204 
LF + MitoVit E 1.219 ± 0.029b 0.567 ± 0.032a 0.829 ± 0.051c 0.325 ± 0.009 11.270 ± 0.179 
MF + MitoVit E 1.188 ± 0.021b 0.706 ± 0.051bc 1.012 ± 0.078b 0.327 ± 0.009 11.430 ± 0.189 
ANOVA            
Block 0.001 0.595 0.186 < 0.001 0.143 
Diet 0.083 < 0.001 < 0.001 0.783 0.280 
Drug 0.043 0.040 0.023 0.054 0.669 
Diet×Drug 0.302 0.970 0.528 0.636 0.617 
1 Values are means ± SEM for 16 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF= medium fat 
diet. 
2 Carcass excludes liver, gastrocnemius, adipose tissues (inguinal and epididymal fat pads), 
skin, feet, head, tail, and viscera. 
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Table 5 Total liver lipid content and whole body lipid and protein contents 1-2 
Treatments Total liver lipid content (%) 
Whole body lipid 
content (g)  
Whole body protein 
content (g) 
LF + placebo 4.646 ± 0.291b 11.570 ± 0.47a 19.120 ± 0.409b 
MF + placebo 5.350 ± 0.187a 13.780 ± 0.82b 18.024 ± 0.407a 
LF + MitoVit E 4.311 ± 0.322b 9.680 ± 0.44a 19.302 ± 0.216b 
MF + MitoVit E 4.585 ± 0.355b 11.410 ± 0.72a 18.680 ± 0.405ab 
ANOVA        
Block < 0.001 0.670 0.007 
Diet 0.053 0.005 0.014 
Drug 0.031 0.002 0.224 
Diet×Drug 0.385 0.629 0.490 
1 Values are means ± SEM for 16 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF= medium fat 
diet. 
2 Whole body was the rest of carcass after liver, gastrocnemius, adipose tissues (inguinal and 
epididymal fat pads), skin, feet, head, tail, and viscera were removed. 
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Table 6 Plasma parameters1-3 
Treatments SOD (fold change)          
GPx             
(fold change)       
   H2O2         
(fold change) 
TAG               
(fold change)      
NEFA          
(fold change)    
LF + placebo 1.000 ± 0.034a 1.000 ± 0.05ab 1.000 ± 0.063bc 1.000 ± 0.106 1.000 ± 0.074 
MF + placebo 0.904 ± 0.036b 0.977 ± 0.038ab 1.207 ± 0.087a 0.86 ± 0.085 0.94 ± 0.054 
LF + MitoVit E 1.014 ± 0.049a 1.129 ± 0.12a 0.897 ± 0.044c 0.921 ± 0.041 1.082 ± 0.216 
MF + MitoVit E 1.051 ± 0.016a 0.877 ± 0.043b 1.144 ± 0.045ab 1.074 ± 0.094 0.831 ± 0.048 
ANOVA            
Block 0.004 0.112 0.509 0.077 0.058 
Diet 0.340 0.058 0.001 0.928 0.341 
Drug 0.014 0.839 0.279 0.418 0.477 
Diet×Drug 0.038 0.109 0.690 0.100 0.676 
1 Values are means ± SEM and values within a column with unlike superscript letters were 
significantly different (P < 0.05). LF = low fat diet; MF = medium fat diet. 
2 Mean values are fold changes relative to LF + placebo group set to 1 unit. 
3 SOD: superoxide dismutase; GPx: glutathione peroxidase; TAG: triacyglycerol; NEFA: 
non-esterified fatty acid. 
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Table 7 Mitochondrial ATP production rate in liver1-2 
Treatments GM           (nmol/min*mg protein) 
GMP         
(nmol/min*mg protein) 
GMPK      
(nmol/min*mg protein) 
LF + placebo 0.360 ± 0.05 0.440 ± 0.048ab 0.300 ± 0.03 
MF + placebo 0.320 ± 0.026  0.410 ± 0.017b 0.270 ± 0.015 
LF + MitoVit E 0.350 ± 0.048 0.530 ± 0.055a 0.342 ± 0.035 
MF + MitoVit E 0.390 ± 0.029 0.500 ± 0.037ab 0.340 ± 0.019 
ANOVA        
Block 0.977 0.358 0.364 
Diet 0.976 0.444 0.624 
Drug 0.419 0.041 0.044 
Diet×Drug 0.333 0.976 0.633 
1 Values are means ± SEM for 8 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 GM, 1 mM glutamate plus 1 mM malate; GMP, 1 mM glutamate plus 1 mM malate plus 
0.005 mM palmitoyl L-carnitine; GMPK, 1 mM glutamate plus 1 mM malate plus 0.005 mM 
palmitoyl L-carnitine plus 10 mM α-ketoglutarate, for details of procedure, see Materials and 
Methods.  
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Table 8 Mitochondrial H2O2 production rate in liver1-2 
Treatments 
GM        
(nmol/min*mg 
protein) 
GM + Rotenone 
(nmol/min*mg 
protein) 
SUC         
(nmol/min*mg 
protein) 
SUC + Antimycin 
(nmol/min*mg 
protein) 
LF + placebo 0.141 ± 0.003ab 0.122 ± 0.007ab 0.146 ± 0.011 0.102 ± 0.011ab 
MF + placebo 0.152 ± 0.007a 0.136 ± 0.006a 0.166 ± 0.016 0.126 ± 0.017a 
LF + MitoVit E 0.129 ± 0.004b 0.111 ± 0.007b 0.139 ± 0.005 0.089 ± 0.005b 
MF + MitoVit E 0.139 ± 0.004b 0.122 ± 0.003ab 0.152 ± 0.012 0.098 ± 0.008ab 
ANOVA          
Block 0.009 0.170 0.226 0.198 
Diet 0.027 0.0416 0.173 0.156 
Drug 0.007 0.0409 0.349 0.060 
Diet×Drug 0.948 0.8545 0.816 0.519 
1 Values are means ± SEM for 8 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 GM, 5 mM glutamate plus 5 mM malate; GM+Rotenone, 5 mM glutamate plus 5 mM 
malate + 10 µM rotenone; SUC, 9 mM succinate; SUC + Antimycin, 9 mM succinate + 10 
µM antimycin. For details of procedures, see Materials and Methods. 
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Table 9 Mitochondrial aconitase activity and protein carbonyl content in liver1 
Treatments Aconitase activity                         (fold change)2 
Protein carbonyl content          
(arbitrary OD units) 
LF + placebo 1.000 ± 0.08 0.495 ± 0.091ab 
MF + placebo 0.970 ± 0.063 0.542 ± 0.089a 
LF + MitoVit E 1.250 ± 0.12 0.278 ± 0.049b 
MF + MitoVit E 1.195 ± 0.116 0.337 ± 0.044b 
ANOVA      
Block 0.425 0.632 
Diet 0.749 0.429 
Drug 0.049 0.008 
Diet×Drug 0.857 0.966 
1 Values are means ± SEM (aconitase, n=6; protein carbonyl, n=8) and values within a 
column with unlike superscript letters were significantly different (P < 0.05). LF = low fat 
diet; MF = medium fat diet. 
2 Fold change relative to LF + placebo group set to 1 unit 
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Table 10 Mitochondrial ATP production rate in muscle1-2 
Treatments GM              (nmol/min*mg protein) 
GMP            
(nmol/min*mg protein) 
GMPK           
(nmol/min*mg protein) 
LF + placebo 6.187 ± 1.31 10.096 ± 2.752 6.223 ± 1.677 
MF + placebo 4.943 ± 1.182 11.047 ± 2.799 5.632 ± 1.71 
LF + MitoVit E 5.320 ± 1.229 10.015 ± 2.509 5.873 ± 1.777 
MF + MitoVit E 6.033 ± 1.148 10.289 ± 2.29 5.793 ± 1.511 
ANOVA        
Block 0.153 0.067 0.143 
Diet 0.909 0.807 0.881 
Drug 0.99 0.762 0.828 
Diet×Drug 0.364 1.000 0.834 
1 Values are means ± SEM for 8 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 GM, 1 mM glutamate plus 1 mM malate; GMP, 1 mM glutamate plus 1 mM malate plus 
0.005 mM palmitoyl L-carnitine; GMPK, 1 mM glutamate plus 1 mM malate plus 0.005 mM 
palmitoyl L-carnitine plus 10 mM α-ketoglutarate, see Materials and Methods.  
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Table 11 Mitochondrial H2O2 production rate in muscle1-2 
Treatments 
GM         
(pmol/min*mg 
protein) 
GM + Rotenone 
(pmol/min*mg 
protein) 
SUC         
(pmol/min*mg 
protein) 
SUC + Antimycin 
(pmol/min*mg 
protein) 
LF + placebo 5.18 ± 0.6ab 21.8 ± 6.6 14.5 ± 2.26 101.8 ± 16.4 
MF + placebo 6.44 ± 0.61a 23.84 ± 6.18 6.42 ± 1.53 77.25 ± 23.59 
LF + MitoVit E 4.21 ± 0.39b 24.94 ± 5.61 14.16 ± 5.11 78.83 ± 15.89 
MF + MitoVit E 5.59 ± 0.6ab 20.95 ± 5.76 16.18 ± 5.78 55.24 ± 19.9 
ANOVA          
Block 0.584 0.022 0.054 0.624 
Diet 0.027 0.858 0.481 0.22 
Drug 0.121 0.709 0.322 0.25 
Diet×Drug 0.911 0.854 0.222 0.977 
1 Values are means ± SEM for 8 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 GM, 5 mM glutamate plus 5 mM malate; GM+Rotenone, 5 mM glutamate plus 5 mM 
malate + 10 µM rotenone; SUC, 9 mM succinate; SUC + Antimycin, 9 mM succinate + 10 
µM antimycin. For details of procedures, see Materials and Methods. 
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Table 12 Mitochondrial aconitase activity and protein carbonyl content in muscle1 
Treatments Aconitase activity                         (fold change)2 
Protein carbonyl content          
(arbitrary OD units) 
LF + placebo 1 ± 0.2a 0.48 ± 0.103 
MF + placebo 0.547 ± 0.07b 0.748 ± 0.163 
LF + MitoVit E 1.039 ± 0.15a 0.454 ± 0.065 
MF + MitoVit E 0.77 ± 0.16ab 0.687 ± 0.131 
ANOVA      
Block 0.011 0.13 
Diet 0.051 0.053 
Drug 0.322 0.728 
Diet×Drug 0.209 0.891 
1 Values are means ± SEM (aconitase, n=6; protein carbonyl, n=8) and values within a 
column with unlike superscript letters were significantly different (P < 0.05). LF = low fat 
diet; MF = medium fat diet. 
2 Fold change relative to LF + placebo group set to 1 unit. 
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Table 13 Mitochondrial number and average size in soleus muscle1-2 
 Intermyofibrillar mitochondria Subsarcolemmal mitochondria 
Treatments 
Number of 
mitochondria 
(number/section) 
Average of 
mitochondria size 
(µm2) 
Number of 
mitochondria 
(number/section) 
Average of 
mitochondria 
size (µm2) 
LF + placebo 17.7 ± 3.7c 0.123 ± 0.023 23.1 ± 1.7c 0.305 ± 0.016ab 
MF + placebo 5.7 ± 1.7a 0.076 ± 0.018 3 ± 0.6a 0.125 ± 0.003a 
LF + MitoVit E 16.3 ± 2.3bc 0.126 ± 0.056 25.7 ± 2.7c 0.397 ± 0.015b 
MF + MitoVit E 7.3 ± 1.1ab 0.104 ± 0.006 15.9 ± 0.1b 0.387 ± 0.113b 
ANOVA          
Diet 0.012 0.342 < 0.001 0.172 
Drug 0.969 0.651 0.009 0.037 
Diet×Drug 0.566 0.716 0.035 0.212 
1 There is no block effect in the ANOVA model because all the mice (8 mice) for microscopy 
are from the same block. LF = low fat diet; MF = medium fat diet. 
2 Values are means ± SEM (n=2, analysis of 5 images per animal, 2 animals per treatment) 
and values within a column with unlike superscript letters were significantly different (P < 
0.05). 
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Table 14 Expression of genes involved in lipid metabolism in liver1-3 
Treatments PPARγ          FAS                 ACCα ACO              CPT1a          
LF + placebo 0.902 ± 0.072a 1.858 ± 0.31b 1.607 ± 0.249a 0.75 ± 0.123a 0.689 ± 0.049a 
MF + placebo 1.295 ± 0.117b 0.877 ± 0.148a 0.697 ± 0.101b 1.228 ± 0.234ab 0.811 ± 0.075ab 
LF + MitoVit E 0.693 ± 0.101a 1.34 ± 0.185ab 1.068 ± 0.123b 1.789 ± 0.582ab 1.013 ± 0.06bc 
MF + MitoVit E 1.344 ± 0.129b 0.966 ± 0.147a 0.804 ± 0.089b 2.238 ± 0.637b 1.191 ± 0.132c 
ANOVA            
Block 0.28 0.256 0.954 0.818 0.391 
Diet < 0.001 0.004 0.002 0.353 0.096 
Drug 0.459 0.31 0.198 0.049 < 0.001 
Diet×Drug 0.237 0.175 0.068 0.977 0.747 
1 Values are means ± SEM for 6 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 Levels of gene expression were mRNA abundance ratio (target gene/β-actin). 
3 PPARγ: peroxisome proliferator-activated receptor γ; FAS: fatty acid synthase; ACCα: 
acetyl-CoA carboxylase α; ACO: acyl-CoA oxidase; CPT1 a: carnitine palmitoyl transferase 
1 a. 
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Table 15 Expression of genes involved in lipid metabolism in adipose tissue (I)1-3 
Treatments PPARγ          FAS                 ACCα ACO              CPT1a          
LF + placebo 0.986 ± 0.037a 0.907 ± 0.171ab 0.917 ± 0.168bc 0.71 ± 0.071b 0.833 ± 0.064a 
MF + placebo 0.833 ± 0.043ab 0.633 ± 0.084a 0.636 ± 0.072ab 0.706 ± 0.07b 0.984 ± 0.041ab 
LF + MitoVit E 0.912 ± 0.07ab 1.309 ± 0.187b 1.089 ± 0.122c 1.04 ± 0.072a 0.94 ± 0.03ab 
MF + MitoVit E 0.799 ± 0.077b 0.516 ± 0.046a 0.545 ± 0.048a 0.798 ± 0.079b 0.984 ± 0.051b 
ANOVA            
Block 0.214 0.577 0.784 0.062 0.455 
Diet 0.04 0.002 0.004 0.08 0.063 
Drug 0.358 0.322 0.735 0.007 0.291 
Diet×Drug 0.745 0.096 0.335 0.088 0.321 
1 Values are means ± SEM for 6 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 Levels of gene expression were mRNA abundance ratio (target gene/β-actin). 
3 PPARγ: peroxisome proliferator-activated receptor γ; FAS: fatty acid synthase; ACCα: 
acetyl-CoA carboxylase α; ACO: acyl-CoA oxidase; CPT1 a: carnitine palmitoyl transferase 
1 a. 
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Table 16 Expression of genes involved in lipid metabolism in adipose tissue (II)1-3 
Treatments LPL        HSL        UCP2       
LF + placebo 1.027 ± 0.087 1.5 ± 0.182b 0.778 ± 0.048a 
MF + placebo 0.997 ± 0.047 1.084 ± 0.104a 0.737 ± 0.027a 
LF + MitoVit E 0.999 ± 0.057 1.21 ± 0.126ab 0.992 ± 0.121b 
MF + MitoVit E 0.856 ± 0.101 0.9 ± 0.092a 0.995 ± 0.04b 
ANOVA        
Block 0.925 0.673 0.603 
Diet 0.315 0.015 0.8 
Drug 0.306 0.1 0.004 
Diet×Drug 0.497 0.723 0.766 
1 Values are means ± SEM for 6 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 Levels of gene expression were mRNA abundance ratio (target gene/β-actin). 
3 LPL: lipoprotein lipase; HSL: hormone-sensitive lipase; UCP2: uncoupling protein 2. 
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Table 17 Expression of genes involved in energy and lipid metabolism in muscle1-3 
Treatments PGC1α     UCP3 CPT1b          ACO 
LF + placebo 1.348 ± 0.133a 1.749 ± 0.164 1.271 ± 0.105 1.838 ± 0.217b 
MF + placebo 1.715 ± 0.163b 1.774 ± 0.239 1.471 ± 0.212 2.121 ± 0.207ab 
LF + MitoVit E 1.642 ± 0.136ab 2.126 ± 0.368 1.407 ± 0.094 2.484 ± 0.236a 
MF + MitoVit E 1.553 ± 0.125ab 2.051 ± 0.401 1.575 ± 0.089 2.309 ± 0.145ab 
ANOVA          
Block 0.006 0.001 0.413 0.589 
Diet 0.264 0.916 0.195 0.797 
Drug 0.579 0.179 0.392 0.06 
Diet×Drug 0.066 0.833 0.906 0.287 
1 Values are means ± SEM for 6 animals per group and values within a column with unlike 
superscript letters were significantly different (P < 0.05). LF = low fat diet; MF = medium fat 
diet. 
2 Levels of gene expression were mRNA abundance ratio (target gene/β-actin). 
3 PGC1α: PPARγ coactivator 1α; UCP3: uncoupling protein 3; CPT1 a: carnitine palmitoyl 
transferase 1 a; ACO: acyl-CoA oxidase;  
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Figure 1. Aconitase inhibition-cascade leads to obesity development. (adapted and 
modified from Wlodek and Gonzales, 2005). Mitochondrial aconitase is oxidized and 
inhibited by ROS, which results in increased mitochondrial citrate levels and decreased 
ATP production. Citrate is transported to cytosol and activates ACC (acetyl-CoA 
carboxylase) and fatty acid synthesis. ACC and malonyl-CoA inhibit CPT I (carnitine 
parmitoyltransferase I) and beta-oxidation. Decreased ATP production leads to 
increased food intake and decreased energy expenditure.  
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Figure 2. Structure of MitoVit E3 (the subscript in the compound refers to the number 
of carbons in the alkyl chain connecting the TPP and antioxidant moieties) 
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Figure 3. Characteristics of mice in the first 4 weeks when fed high fat diet before 
treatment. (A) Body weight (g/day*mouse, n=64). (B) Feed intake (g/day*mouse, n=64). 
(C) Urinary isoprostane/creatinine (10-6, n=48). WK= week. *Week: P<0.05. 
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Figure 4. Growth performance of mice after treatment. (A) Effect of diet on body 
weight gain, n=32 (B) Effect of MitoVit E on body weight, n=32 (C) Effect of diet on 
feed intake, n=32, and (D) Effect of MitoVit E on feed intake, n=32. Light grey 
represents pretreatment; Dark gray represents low fat diet group (A and C) or placebo 
group (B and D); Black represents medium fat diet group (A and C) or placebo group 
(B and D). WK= week. # Diet: P < 0.05; * Drug: P < 0.05. 
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Figure 11. Effect of MitoVit E and medium fat diet on urinary isoprostane/creatinine. 
(A) Effect of diet on decrease of urinary isoprostane/creatinine (10-6, n=14), (B) Effect of 
MitoVit E on decrease of urinary isoprostane/creatinine (10-6, n=14). Dark gray 
represents low fat diet group (A) or placebo group (B); Black represents medium fat 
diet group (A) or placebo group (B). # Diet: P < 0.05; * Drug: P < 0.05. 
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Figure 12. Representative immunoblots of mitochondrial protein carbonyl in liver (A) and muscle 
(B), n=8. MF represents medium fat diet group; LF represents low fat diet group; - represents 
placebo group; + represents MitoVit E group; M represents marker of protein standards. # Diet: P< 
0.05; * Drug: P< 0.05. 
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Figure 13. Intermyofibrillar and subsarcolemmal mitochondrial density assessed by 
transmission electron microscopy in the soleus muscle of mice. Original magnification, 
×4000, analysis of 5 images per animal, 2 animals per treatment. 
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GENERAL SUMMARY 
General discussion and future research 
Mitochondria are central to cell life and death not only because they are heavily 
involved in energy metabolism as a “powerhouse” to every cell, but also they play important 
roles in programmed cell death (apoptosis) (1), redox metabolism (2,3), and iron and calcium 
homeostasis (1, 4). However, on the other hand, mitochondria are also the major site of ROS 
production in the cell and the prime targets for oxidative damage (5). Once mitochondrial 
ROS production overwhelms mitochondrial enzymatic and nonenzymatic antioxidant 
systems, oxidative damage to those functional lipids, proteins, and nucleic acids in the 
mitochondria can occur, leading to cell dysfunction and apoptosis.  
Among those mitochondrial proteins, mitochondrial aconitase is particularly 
susceptible to oxidative damage (6) because the electrophilicity of the fourth labile iron atom 
in its labile Fe-S cluster renders it especially sensitive to oxidative inactivation by 
nucleophilic O2.-. Interestingly enough, aconitase’s susceptibility to oxidative damage was 
interpreted differently by different researchers. Walden proposed from the perspective of 
evolutional significance that higher sensitivity of mitochondrial aconitase to oxidative 
inactivation can provide a feedback mechanism to protect DNA and cell membranses from a 
potentially lethal oxidative attack by slowing the Krebs cycle and decreasing electron flux 
through the ETC and resultant ETC-derived O2.- (7).  This idea is very consistent with the 
“aconitase as a circuit breaker” theory proposed by Gardner and Fridovich back in 199l (8). 
In contrast, Yan et al. proposed a completely opposite mechanism that oxidative inactivation 
of aconitase, instead of alleviating oxidative stress, would initiate a cascade with the potential 
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to cause a dramatic increase in the cellular burden of oxidative damage (6). These two 
seemingly paradoxical mechanisms could be explained by our hypothesis that there might be 
two different aconitase inactivation cascades under both normal and pathophysiological/ 
ageing conditions. Under normal redox conditions, the release of aconitase iron by O2.- and 
the resultant inactivation of its activity can be reversed and therefore inactivation of aconitase 
by O2.- can initiate a feedback mechanism to alleviate the oxidative stress attack. However, 
under some pathophysiological conditions in oxidative stress-induced diseases, elevation in 
the rate of superoxide generation and resultant enhancement in the production of H2O2 and 
hydroxyl free radical may cause carbonylation and an irreversible inactivation of aconitase 
through metal-dependent, site-specific oxidations (9); therefore, inactivation of aconitase by 
O2.- can result in a feedforward loop to deteriorate the present oxidative damage. Our 
hypothesis is further supported by recent findings that inhibition of aconitase has been 
proposed to be one of the mechanisms contributing to ageing (6), obesity development (10), 
and PD (1), confirming that the aconitase inhibition cascade under pathophysiological/ageing 
conditions is different from that evolutionally advantageous cascade found under normal 
conditions. 
In this study, our central hypothesis was that oxidative stress might contribute to 
obesity development mediated by aconitase inhibition. This central hypothesis was also on 
the basis of an “aconitase inhibition cascade” proposed by Wlodek and Gonzales (10) that 
inhibition of mitochondrial aconitase could increase lipogenesis, slow lipolysis, increase feed 
intake, and decrease energy expenditure, which together might cause more lipid deposition 
and obesity development. We tested this central hypothesis experimentally in two different 
fashions by using medium fat diet and mitochondrially targeted vitamin E (MitoVit E). 
            
 
112
Specifically, we hypothesized that medium fat diet contributes to obesity development by 
initiating the aconitase inhibition cascade, whereas MitoVit E can improve obesity 
development by reversing the aconitase inhibition cascade.  
Consistent with our hypothesis, medium fat diet increased muscle mitochondrial 
H2O2 production rate, consequently decreased aconitase activity, and increased protein 
carbonyl contents, whereas MitoVit E inversely decreased hepatic mitochondrial H2O2 
production rate, increased aconitase activity, and decreased protein carbonyl contents. 
Inconsitent with our hypothesis, medium fat diet instead decreased gene expression of ACC 
and FAS involved in de novo lipogenesis whereas MitoVit E did not affect expression of 
these two genes. In addition, MitoVit E enhanced beta-oxidation indicated by elevated 
CPT1a expression in the liver, which, however, was not mediated by the decrease of ACC 
and malonyl CoA as we hypothesized. Therefore, we can see that the effectiveness of this 
“aconitase inhibition cascade” was only limited within the mitochondria. Our explaination 
for the above inconsistency is 1) medium fat diet can easily supply the body’s need for fat 
without a need to initiating de vovo lipogenesis, which could explain that medium fat diet 
decreased all these genes involved in lipogenesis; 2) the unsuccessful accumulation of 
cytosolic citrate when mitochondrial aconitase is inhibited by ROS could possibly explain 
that the alleviation of ROS-induced aconitase inhibition by MitoVit E failed to affect those 
cytosolic genes involved in lipogenesis. This possibility does exist because mitochondrial 
citrate could bind to the labile iron released from Fe-S cluster as a low-molecular-weight iron 
chelator when aconitase is oxidized by ROS (1) and be trapped within the mitochondria, 
instead of being transferred to cytosol for turning on the lipogenesis. However, future studies 
need to 1) evaluate cytosolic citrate to testify whether the “aconitase inhibition cascade” is 
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correct or not and 2) investigate how MitoVit E increased CPT1a expression in the liver 
without affecting the activity of ACC (obviously not via AMPK pathway).  
In addition, future study also need to find out the reason why mitoVit E increased 
mitochondrial ATP production rate in liver but it did not affect feed intake because this 
finding is inconsistent with those studies (11-13) reporting that hepatic ATP concentrations, 
which act as a major sensor of energy status in the body, are inversely related to food intake. 
MitoVit E acts in a tissue-specific manner to reduce the mitochondrial oxidative stress with 
higher efficacy in liver than in muscle. We speculate that this tissue specificity might be 
attributed to their different uptakes of MitoVit E and needs confirmation from future study. 
Our body composition data indicates that like interleukin 15 (IL-15), MitoVit E plays a role 
in energy partitioning by favoring elevated energy expenditure in adipose tissue and 
preserving energy storage in skeletal muscle. Future work in our laboratory will investigate 
the role of MitoVit E in regulating IL-15 and other cytokines involved in this muscle-fat 
endocrine axis. Our unexpected finding that MitoVit E increased peroxisomal fatty acid 
oxidation in liver, adipose tissue, and muscle (P = 0.06) needs more investigation in the 
future. Finally, why did MitoVit E have no effect on mitochondrial H2O2 production rate in 
the gastrocnemius but it could normalize the decrease of subsarcolemmal mitochondrial 
density in soleus induced by medium fat diet? Does this have to do with the different fiber 
types in two muscles (red oxidative soleus vs. white glycolytic gastrocnemius)? And could 
MitoVit E restore the altered subsarcolemmal mitochondrial density by some other unknown 
properties other than as an antioxidant? These questions need to be addressed in our future 
research. 
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